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1. Introduction 
1.1.  Hypoxic pulmonary vasoconstriction 
Hypoxic pulmonary vasoconstriction (HPV) is unique to the pulmonary circulation and 
redistributes blood flow from areas of low oxygen partial pressure to areas of normal 
or relativity high oxygen availability, thus optimising the matching of perfusion and 
ventilation and preventing arterial hypoxemia.
1,2 HPV was first described by Von 
Euler and Liljestrand in 1946 who ventilated cats with an hypoxic gas mixture and 
recorded an increase in pulmonary artery pressure (PAP).
3 The strength of HPV is 
now known to depend on species, age, gender, pCO2 and pH and the precapillary 
smooth muscle cells of resistance pulmonary arteries have been identified as effector 
cells. The exact molecular identity of the pulmonary oxygen sensor and the signalling 
cascade leading to hypoxic pulmonary vasoconstriction, however, remain to be fully 
elucidated.
4 HPV is initiated within seconds of moderate hypoxia and reverses 
quickly on restoration of normoxic ventilation.
5 Longer periods of hypoxia elicit a 
biphasic response consisting of a rapid constriction (phase 1) followed by a 
temporary vasodilation and a secondary slowly developing sustained contraction 
(phase 2) which can last for hours or even days if hypoxia is maintained.
6 At present 
it is not clear whether the acute hypoxic vasoconstriction and the prolonged response 
to hypoxia are regulated by identical or different mechanisms.
7 
In clinical situations, HPV may occur either as an acute episode during rapidly 
progressive critical illnesses or as a sustained response with pulmonary hypertension 
in progressive lung diseases.
8 Widespread alveolar hypoxia occurs as a result of 
many lung illnesses (e.g. asthma, inhalation of foreign objects, chronic obstructive 
pulmonary disease, emphysema), acute lung damage (e.g. pneumonia, acute 
respiratory distress syndrome) or as a consequence of movement to high altitude. 
Chronic hypoxia results in a sustained increase in pulmonary artery pressure which 
in turn leads to structural changes in the walls of the pulmonary vasculature 
(pulmonary vascular remodelling). 
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1.2.  Hypoxia-induced pulmonary vascular remodelling 
Under normal conditions, the thickness of the vascular wall is maintained at an 
optimal level by a fine balance between proliferation and apoptosis of the resident 
cell types. If this balance is disturbed in favour of proliferation, the vascular wall 
thickens and eventually obliterates the vessel lumen, leading to increased resistance. 
It is accepted that hypoxia is a cause of pulmonary vascular proliferation and 
vascular remodelling, but the mechanism remains unclear. Generally it is believed 
that the contribution of vasoconstriction is greatest early in the disease process and 
that structural remodelling of the pulmonary vascular bed becomes progressively 
important with time.
9 Remodelling processes include an increase in the extent of 
pulmonary artery muscularisation which is attributed to the increased proliferation 
and decreased apoptosis of pulmonary artery smooth muscle cells, media 
hypertrophy and eccentric intimal fibrosis,
10,11 and is thought to result from an 
alteration in the balance between the effects of vasodilators and antiproliferative 
agents and vasoconstrictors and mitogenic factors.
12 
Hypoxia activates a cascade of intracellular signalling mechanisms, including 
receptor and nonreceptor tyrosine kinases, mitogen-activated protein kinases 
(MAPK), protein kinase C (PKC), phosphotidylinositol 3-kinase (PI3K), SMAD 
phosphorylation, calcium (Ca
2+) entry and Rho kinase, which collectively act to 
control smooth muscle cell contractility, growth, differentiation, and matrix 
synthesis.
13 Changes in receptor expression or function as well as in Ca
2+ handling 
have been observed in smooth muscle cells from pulmonary hypertensive patients.
14 
Chronic hypoxia is also reported to downregulate the expression of Kv channels and 
upregulates the expression of canonical transient receptor potential (TRPC) channels 
in pulmonary artery smooth muscle cells
14,15 causing an increase in intracellular Ca
2+ 
leading to pulmonary vasoconstriction. Furthermore, Kv downregulation is reported to 
be proliferative and anti apoptotic.
15,16 
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Figure 1: Scheme illustrating the hypoxic signalling pathways that lead to vascular 
remodelling of the pulmonary artery. 5-HT: 5-hydroxytryptamine; BMPR-II: bone 
morphogenetic protein receptor type II; RTK: receptor tyrosine kinase; P: phosphate; R: 
receptor; G: G protein; PLC: phospholipase C; SH: Src homolgy; Grb: growth factor receptor-
bound protein; GRF: guanine nucleotide releasing factor; PKC: protein kinase C; IP3: inositol-
1,4,5-trisphosphate; DAG: diacylglycerol; MLK: mixed lineage kinase; HIF: hypoxia-inducible 
factor; TRPC: canonical transient receptor potential channels (modified from Pak 2007).
9 
 
The severity of chronic hypoxic pulmonary hypertension and remodelling is largely 
determined by the extent of the structural changes in the media of the pulmonary 
arterial wall. Diverse molecular mechanisms are involved in hypoxia-induced 
pulmonary vascular remodelling (Figure 1). Chronic exposure to hypoxia is also 
associated with a number of changes in the production and release of potent 
vasoactive substances by the endothelium which can exert significant effects not only 
on the contractile state of smooth muscle cells but on their proliferative state as 
well.
13 For example, decreased production of nitric oxide (NO) and prostacyclin 
(PGI2) have been reported
17 as well as increased production of platelet activating 
factor (PAF), 5-hydroxytryptamine (5-HT), leukotrienes, endothelin, platelet derived 
growth factor (PDGF), and transforming growth factor-β (TGF-β).
13,18 5-HT is a 
vasoactive and mitogenic factor and several studies have shown a role for the 5-HT 
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transporter (5-HTT) and 5-HT1 and 5-HT2B receptors in chronic hypoxia-induced 
pulmonary vascular remodelling.
12,19-23  
 
1.3. Oxygen  sensors   
Although the importance of HPV for the optimisation of pulmonary gas exchange was 
recognised relatively early, the molecular identity of the pulmonary oxygen sensor 
and the signalling cascade that initiates pulmonary artery smooth muscle contraction 
have not yet been identified. Current thinking tends to attribute the role of O2 sensor 
to the mitochondria or the NADPH oxidase. Effectors are thought to be potassium 
channels, Ca
2+ channels and the Rho kinase. Moreover, we recently reported that 
Cytochrome P450 (CYP) epoxygenase-derived epoxyeicosatrienoic acids (EETs) are 
involved in mediating HPV (Figure 2).
24 
 
 
B  A 
Figure 2: Current concepts of the oxygen sensing of hypoxic pulmonary 
vasoconstriction.  Possible oxygen sensors are shown in green, mediators of hypoxic 
pulmonary vasoconstriction (HPV) in yellow. pO2: oxygen partial pressure; Δψ: mitochondrial 
membrane potential; SR: sarcoplasmic reticulum; HETE: hydroxyeicosatetraenoic acid; EET: 
epoxyeicosatrienoic acid; Em: cellular membrane potential. (A) Includes those concepts that 
comprise a decrease in reactive oxygen species (ROS) as a trigger for HPV (red lines), (B) 
those that comprise an increase in ROS as a trigger for HPV (blue lines; modified from 
Weißmann 2006).
4 
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The mitochondria are the main site of cellular oxygen consumption as well as energy 
generation and determine the cellular redox state. There are additional arguments 
that favor a role of the mitochondria as primary oxygen sensors. For example, 
inhibition of the mitochondrial electron transport chain blocks HPV, and pulmonary 
artery smooth muscle cells (PASMC) that lack a functional electron chain fail to show 
hypoxic-specific responses.
25-27 Different theories exist concerning the role for 
mitochondria in HPV.
28 Several groups propose that hypoxia decreases 
mitochondrial reactive oxygen species (ROS) production thus shifting the cellular 
redox state to a more reduced state and stimulating the closure of Kv channels which 
leads to depolarisation of the PASMC membrane potential.
26,29-32 Other investigators 
have provided evidence indicating that in PASMCs mitochondrial radical production 
increases during hypoxia and triggers the release of intracellular Ca
2+ thus causing 
HPV.
6,27,33 A role for adenosine triphosphate (ATP) as a second messenger for HPV 
has also been suggested since the electron transport chain is the main oxygen 
consumption site in the cell. Indeed a recent theory postulates that hypoxia 
decreases ATP production, thus increasing the adenosine monophosphate 
(AMP)/ATP ratio in PASMCs. The latter imbalance results in the activation of the 
AMP-activated kinase and increases cyclic adenosine diphosphate (cADP)-ribose 
which then releases Ca
2+ through ryanodine-sensitive Ca
2+ stores.
34,35 However, a 
link between HPV and the latter signalling cascade still needs to be definitely 
demonstrated. Mitochondria also play a role in PASMC cytosolic Ca
2+ homeostasis 
through a Ca
2+ uniporter that is driven by the mitochondrial membrane potential, and 
the concentration of cytosolic Ca
2+.
36 Indeed, a decrease in membrane potential due 
to hypoxia-impaired respiration induces a mitochondrial Ca
2+ release thus triggering 
HPV.
28  
Given the link between hypoxia and ROS production, it is not surprising that another 
potential O2 sensor are the NADPH oxidases (NOX). The latter are a family of 
superoxide anion (O2
-)-generating enzymes, of which several NOX isoforms have 
been identified.
37 Interest in the concept of that the NOXs could act as oxygen 
sensors for HPV emerged following reports that NOX inhibition, using 
diphenyleneiodonium or apocynin, two relatively unspecific NOX inhibitors, blocked 
HPV.
38,39 Currently two diverging concepts regarding the role of NOX in oxygen 
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sensing exist. The first postulates that hypoxia upregulates NOX-derived O2
- 
production triggering the release of intracellular Ca
2+ in PASMCs thus causing 
pulmonary vasoconstriction. The second assumes that hypoxia decreases NOX-
derived O2
- production and subsequent H2O2 generation which in turn attenuates the 
activity of the soluble guanylate cyclase (sGC) leading to a decrease in PASMCs 
cGMP-levels and consequently vasoconstriction.
4 
 
1.4.  Cytochrome P450 enzymes 
Cytochrome P450 enzymes are membrane-bound, heme-containing terminal 
oxidases and are part of a multi-enzyme system that also includes an FAD/FMN-
containing NADPH-CYP reductase and a cytochrome b5. CYP enzymes oxidise, 
peroxidise and/or reduce cholesterol, vitamins, steroids, xenobotics and different 
pharmacological substances in an oxygen and NADPH-dependent manner.
40 CYP 
enzymes are typical monooxygenases in that the enzymatic cleavage of molecular 
oxygen is followed by the insertion of a single atom of oxygen into the substrate while 
the remaining oxygen is released as water (Figure 3).
41 
Cytochrome P450 enzymes are ubiquitously expressed and are widely distributed in 
plants, insects and animal tissues. While in animals, most CYP enzymes are mainly 
expressed in the liver, lower levels of CYP enzymes are expressed in extra-hepatic 
tissues, such as the heart, the vasculature, the gastrointestinal tract and the lung.
42-46 
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Figure 3: Catalytic cycle of cytochrome P450 enzymes. (1) Substrate (R) binding (Fe
3+-
RH). (2) Cytochrome P450 reductase-dependent one electron reduction of the heme iron 
(Fe
2+-RH). (3-4) Binding of molecular oxygen, oxidation of the heme iron (Fe
3+) and transfer 
of the second electron to the complex. (3a) During this step generation of superoxide anions 
can occur. (5) Cleavage of the O-O bound with the concurrent incorporation of the distal 
oxygen atom into a molecule of water and the formation of a reactive iron-oxo species. (6-7) 
Oxygen atom transfer from the oxo complex to the substrate and dissociation of the product 
(8). (9) Peroxide shunt: hydroxylation of peroxides by CYP enzymes (from Davydov 2001).
47 
 
To-date more than 500 CYP isoforms have been identified.
48 The nomenclature of 
the various enzymes can be quite confusing. Proteins with approximately more than 
40% homology in their sequence are included in the same family which is designated 
by an Arabic number. Proteins with more than 55% identity are grouped together in 
the same subclass as designated by a capital letter, the last number identifies 
specific gene products.
40 
Since it was recognised that many CYP isoforms are capable of metabolizing 
arachidonic acid to biologically active products, CYP enzymes have also been 
described as the third pathway of arachidonic acid metabolism; i.e., in addition to 
cyclooxygenases and lipoxygenases. CYP enzymes with an important role in 
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cardiovascular function are the epoxygenases of the CYP2C and 2J gene families 
and the ω-hydroxylases of the CYP4A family.  
 
1.5.   Cytochrome P450-derived arachidonic acid metabolites 
CYP epoxygenases metabolise arachidonic acid to four regioisomeric 
epoxyeicosatrienoic acids (5,6-, 8,9-, 11,12-, and 14,15-EET) (Figure 4). The ratio of 
the produced EET isomers is dependent on the CYP isoform. The CYP2C8 isoform 
produces 14,15- and 11,12-EET in a ratio of 1.25:1. CYP2C9 produces 14,15-, 
11,12-, and 8,9-EET in a ratio of 2.3:1:0.5, whereas the CYP2J2 isoform produces 
5,6-, 8,9-, 11,12-, and 14,15-EETs with equal efficiency.
45,49 In contrast to the 
epoxygenases, the ω-hydroxylases metabolise arachidonic acid sub-terminally and 
ω-terminally to hydroxyeicosatetraenoic acids (HETE).
50 Other CYP enzymes for 
example the rat CYP4A2 and 4A3 are able to generate both EETs and HETEs.
51 
After their generation EETs can be incorporated into phospholipids, mainly 
phosphatidylcholine- and phosphatidylinositol-phospholipids.
52-54 These 
phospholipids are thought to be an intracellular reservoir for EETs.
55 The magnitude 
of endogenous EET levels was thought to depend on CYP activity. As inhibition of 
the phospholipase A2 attenuated the CYP-dependent endothelium-derived 
hyperpolarising factor (EDHF) responses, CYP-activity was thought to be determined 
by the availability of its substrate (arachidonic acid).
40 However, phospholipases are 
not the only enzymes that control intracellular levels of CYP-derived metabolites. 
EETs can also be metabolised to various products. 5,6-EET is the chemically least 
stable arachidonic acid epoxide and is also metabolised by the cyclooxygenase,
56 
whereas all other EET regio-isomers are degraded to their less active 
dihydroxyeicosatrienoic acids (DHET) by epoxide hydrolases (EH) (Figure 4).
57 
Epoxide hydrolases exist as microsomal (mEH) and as soluble (sEH) isoforms. The 
sEH metabolises EETs most efficiently and therefore inhibition or deletion of the sEH 
increases EET levels.
58 There are alternative, less efficient ways of controlling 
cellular EET levels; for example β-oxidation or C2 elongation.
59  
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Figure 4: Overview of the pathways for regulating cellular levels of cytochrome P450-
derived metabolites of arachidonic acid (modified from Quilly 2000).
60 
 
In the systemic circulation, 20-HETE and the EETs play an important role in the 
regulation of vascular tone.
48 EETs act as anti-inflammatory mediators and EDHF 
mediating NO and PGI2-independent but endothelium-dependent vasodilatation in 
some vascular beds.
61,62 A number of studies have examined the mechanism by 
which EETs reduce vascular tone. The first well documented effect was the activation 
of Ca
2+-activated K
+ (K
+
Ca) channels on vascular smooth muscle cells to elicit 
hyperpolarisation and relaxation.
40,61 Although several groups have demonstrated 
that all of the EET regioisomers are potent vasodilators in bovine and porcine 
coronary arteries
63,64 this is not the case in all vascular beds. For example, in feline 
cerebral arteries, the vasodilator response to 11,12-EET is greater than seen with 
8,9- or 5,6-EET
65 and in rat cerebral and caudal arteries 5,6-EET is a more effective 
dilator than the other regioisomers.
66,67 The molecular mechanisms involved in 
mediating the EET-induced activation of K
+
Ca channels are not entirely clear. EETs 
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can affect the activity of at least two different classes of TRP channels (TRPV 
(Vanilloid) and TRPC). For example, 5,6- and 8,9-EET but not 11,12-EET were 
reported to modulate the activity of TRPV4, a channel implicated in 
mechanotransduction.
68 Moreover, our group recently demonstrated that 11,12-EET 
modulates the agonist-induced hyperpolarisation of endothelial cells by a mechanism 
related to cyclic adenosine monophosphate (cAMP)/protein kinase A (PKA) activation 
and TRPC6 translocation.
69 Thus the diversity in EET regioisomer-induced 
responses would be expected to depend on the TRP channels expressed. 20-HETE, 
on the other hand, constricts renal, cerebral, coronary and mesenteric arteries by 
inhibiting K
+
Ca channels, thereby promoting Ca
2+ entry by depolarising vascular 
smooth muscle cells, by increasing the conductance of L-type Ca
2+ channels and by 
ctivating the Rho kinase.
48,70  
 
1.6.  eicosatetraenoic and epoxyeicosatrienoic 
ry tissue, 
en 
a
Effects of hydroxy
acids in the lung 
Although, data from numerous groups have implicated CYP-derived metabolites as 
modulators of vascular tone and other biological effects in the nonpulmona
the role of CYP-derived eicosanoids in the lung is incompletely understood. 
CYP epoxygenase-derived metabolites have been reported to modulate airway 
epithelial ion transport,
71,72 activate K
+
Ca channels in airway smooth muscle cells
73 
and dilate guinea pig bronchi.
74 The bronchomotor effect of 20-HETE seems to be 
complicated as 20-HETE dilated rabbit and human bronchi, but exerted the opposite 
effect in guinea pig bronchi.
42,75-77 Such contradictory reports seem to characterise 
the field at the moment as divergent findings have been published regarding a giv
metabolite dependent on the species, the size of the vessel and the model used.  
20-HETE was found to elicit a dose-dependent and indomethacin-sensitive 
vasodilation of isolated small human pulmonary arteries,
78 while in the rabbit it 
relaxed phenylephrine-constricted pulmonary artery rings. Inhibition of CYP4A 
enhanced the acute HPV in isolated buffer-perfused rabbit lungs and shifted the 
phenylephrine concentration-response curve to the right.
79 In the ovine fetal lung 
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inhibition of 20-HETE formation decreased the myogenic response
80 and in piglet 
pulmonary resistance arteries 20-HETE caused a potent vasoconstriction, a 
89 and 11,12-EET and 
 and both effects were sensitive to 
the specific CYP2C9 inhibitor sulfaphenazole.
24 
response that has been linked to the cyclooxygenase prostaglandin pathway.
81 
5,6-EET caused a relaxation of isolated rabbit pulmonary artery rings and lungs a 
response that has been linked to NO and prostaglandin production.
82,83 Whereas 
others have reported that all EET regioisomers constrict isolated pressurised rabbit 
pulmonary artery rings and that inhibition of rabbit pulmonary CYP epoxygenases 
shifted the phenylephrine concentration-response curve to right.
79,84 The signalling 
pathway underlying EET-induced vasoconstriction seems to involve the Rho kinase 
as the 5,6-EET-induced contraction of intralobar rabbit pulmonary arteries was 
reportedly sensitive to Rho kinase inhibition.
85 In piglets, 5,6-EET was reported to 
dilate pulmonary resistance arteries via the activation of small and intermediate K
+
Ca 
channels.
86 Others have reported that 5,6-EET reduces the thromboxane A2 
analogue U46619-mediated increase in pulmonary vascular resistance in the isolated 
canine lung,
87 and relaxes canine pulmonary venous rings, an effect that was 
sensitive to cyclooxygenase inhibition.
88 In the rat, all EET regioisomers elicit an 
increase in wall tension of isolated pulmonary artery rings
14,15-EET are reported to enhance pulmonary resistance.
90  
Recently, our group demonstrated that a CYP epoxygenase is implicated in hypoxia-
induced pulmonary vasoconstriction and pulmonary remodelling in the mouse.
24 In 
the latter study it was possible to demonstrate that the mediator involved in acute and 
chronic hypoxia-induced pulmonary vasoconstriction and chronic hypoxia-induced 
pulmonary vascular remodelling was a CYP epoxygenase-derived product, as 
inhibition of this enzyme decreased the acute and chronic HPV response and 
attenuated chronic hypoxia-induced pulmonary remodelling.
24 Moreover, as inhibition 
of the sEH enhanced the acute HPV response the potential mediator might be one of 
the EETs. Furthermore, hypoxia up to 1 week enhanced pulmonary levels of 8,9-, 
11,12- and 14,15-EET without affecting 5,6-EET concentrations. Furthermore, lung 
specific gene transfer of the human CYP2C9 significantly enhanced right ventricular 
systolic pressure and total pulmonary resistance
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In the lung, more precisely in endothelial cells and human bronchi EETs display anti-
inflammatory properties. Indeed, the overexpression of CYP2J2 in endothelial cells or 
application of 11,12-EET to uninfected endothelial cells decreased cytokine-induced 
endothelial cell adhesion, molecule expression and prevented leukocyte adhesion to 
the vascular wall by a mechanism involving inhibition of the transcription factor 
nuclear factor κB (NFκB) and the inhibitor of κB (IκB) kinase.
91 In tumor necrosis 
factor-α (TNF-α) stimulated human bronchi 14,15-EET also displayed anti-
inflammatory effects, again attributed to the inhibition of the IκB degradation, 
suggesting a lower activation of NFκB.
92 
 
1.7. Soluble  epoxide  hydrolase 
The soluble epoxide hydrolase which metabolises fatty acid epoxides (EETs, 
leukotriene A4; LTA4, epoxyoctadecenoic acids; EpOME, and epoxystearic acid; 
EpO) to their corresponding diols belongs to the α/β-hydrolase enzyme family (Figure 
5). The enzyme was termed cytosolic and later soluble epoxide hydrolase because of 
its localisation in the soluble fractions of the cell. 
In mammals the sEH is a homodimer composed of two 60kDa monomers joined by a 
proline rich bridge and is the product of the EPHX2 gene.
93-95  Each monomer has an 
N-terminal domain which displays lipid phosphatase activity and a larger C-terminal 
which processes classical α/β-hydrolase activity.
95,96 Although the biological role of 
the N-terminal lipid phosphatase activity remains unclear, the loss of sEH activity 
results in increased circulating levels of EETs and a decrease in DHET production. 
Tissues with high sEH expression are the liver, the kidney and the retina, but the 
enzyme is also expressed by some endothelial cells, smooth muscle cells, pancreatic 
islets and leucocytes.
97,98 There are different factors that regulate sEH expression 
including gender, hormones and genetic background. For example, sEH activity is 
increased in male mice versus female mice and rats, and castration decreased sEH 
activity and expression; a phenomenon restored by testosterone 
supplementation.
99,100 Moreover, there is a clear link to cardiovascular diseases as 
renal microsomes from spontaneously hypertensive rats displayed an increased sEH 
expression
101 and inhibition of the sEH in spontaneously hypertensive rats blunted 
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the development of hypertension.
101-103 Interestingly, angiotensin II increases 
vascular sEH expression and pharmacological sEH inhibition prevented or reversed 
angiotensin II-induced hypertension in mice and rats.
104,105 
 
 
Figure 5: Activity of mammalian sEH with various fatty acid epoxides. EET: 
epoxyeicosatrienoic acid; LTA4: leukotrien A4; EpOME: epoxy octadecenoic acids; EpO: 
epoxystearic acid (from Newman 2005).
106 
 
There are several reported polymorphisms in the sEH gene that affect the enzymatic 
function
107 and that have been linked to cardiovascular disease.
108,109 For example, 
individuals carrying the K55R polymorphism demonstrated higher soluble epoxide 
hydrolase activity in vivo and a significantly higher risk of coronary heart disease.
110 
On the other hand, three polymorphisms in the EPHX2 promotor that resulted in 
decreased sEH mRNA expression and activity were associated with the increased 
incidence of stroke in the rat;
111 an observation not entirely consistent with a 
predominantly anti-inflammatory effect of the sEH substrates. Another interesting 
observation is the link between sEH expression and cigarette smoking, a well known 
risk factor for cardiovascular diseases, and which increases sEH expression.
112 More 
recently, EPHX2 was characterised as a heart failure susceptibility gene in the 
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spontaneously hypertensive rat and ablation of the gene in the mouse protected from 
pressure overload-induced heart failure and cardiac arrhythmias.
113 The latter 
findings could be correlated with EPHX2 downregulation in human failing hearts 
which could be interpreted as an adaptive transcriptional process aimed at 
maintaining high levels of cardioprotective  EETs.
113,114 
 
1.8. TRP  channels 
Transient receptor potential (TRP) channels have been linked to hypoxic pulmonary 
vasoconstriction
115 and can be activated by specific EETs.
69,116,117 To-date the TRP 
family of ion channels consists of nearly 30 mammalian members,
118 all belonging to 
the superfamily of cation channels formed by tetramers of six transmembrane 
domains which enclose a pore near the C-terminal and function as voltage-
independent, non-selective cation channels, i.e., permeable to Na
+, K
+, Cs
+, Li
+, Ca
2+, 
and Mg
2+.
119,120 Different TRP channels gate in response to different stimuli (e.g. cold 
or hot temperatures, natural chemical compounds, mechanical stimuli, or changes in 
the composition of the lipid bilayer). They play a crucial role in numerous 
physiological processes e.g. photoreception, pheromone sensing, taste perception, 
thermosensation, pain perception, mechanotransduction, perception of pungent 
compounds, renal Ca
2+/Mg
2+ handling, smooth muscle tone and blood pressure 
regulation.
121  
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Figure 6: Phylogenetic tree of the TRP superfamily. Based on amino acid homology, TRP 
channels can be divided into seven subfamilies: TRPC (Canonical, TRPC1-TRPC7), TRPM 
(Melastatin, TRPM1-TRPM8), the TRPV (Vanilloid) subfamily comprises six members 
(TRPV1-TRPV6), the TRPML (Mucolipin) familiy comprises three members, the TRPP 
(Polycystin) family three channel-like and five non-channel members, the TRPA (Ankyrin, A1) 
and the TRPN (only detected in C. elegans, Drosophila and zebra fish; from Pedersen 
2005).
122 
 
Based on their amino acid homology TRP channels can be divided into seven 
subfamilies (Figure 6). The TRPC (Canonical) family consists of seven different 
channels (TRPC1-TRPC7) while the TRPM (Melastatin) channels consist of eight 
different proteins (TRPM1-TRPM8). The TRPV (Vanilloid) subfamily comprises six 
members (TRPV1-TRPV6) while the TRPML (Mucolipin) familiy has currently three 
members and the TRPP (Polycystin) family three channel-like and five non-channel-
like members. The TRPA (Ankyrin) has one member and the TRPN (no 
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mechanoreceptor potential C) has only been detected in C. elegans, Drosophila and 
Zebrafish.
122 
TRPC channels are broadly expressed and one cell type can contain multiple TRPC 
channels.
119,122 On the basis of sequence homology and functional similarities 
members of the mammalian TRPC family can be divided into four subfamilies; 
TRPC1, TRPC2, TRPC3/6/7 and TRPC4/5.
123 A functional TRPC channel is formed 
by association of four TRPC proteins and can form as homotetramers or as 
heterotetramers. For example, TRPC1 can form heteromers with TRPC4 and 5, and 
the TRPC subfamilies TRPC4/5, and TRPC3/6/7 can form heteromers among 
themselves.
122 Although the molecular organisation is complex, the evidence that 
TRPC channels are linked to HPV is convincing and using pharmacological agents 
(SKF-96365, Ni
2+ and La
3+) to block Ca
2+ influx through non-selective cation 
channels in PASMCs a potent inhibition of HPV was demonstrated at concentrations 
that did not affect voltage-gated Ca
2+ channels.
124 Along the same lines, TRPC1 
overexpression enhances pulmonary artery contraction to cyclopiazonic acid and 
small interfering RNAs targeted to mRNA encoding TRPC4 suppresses store-
operated Ca
2+ influx in pulmonary artery myocytes in culture, without having an effect 
on background [Ca
2+]i or Ca
2+ release signals.
125,126 Moreover, TRPC6 was found to 
be upregulated in hypoxia-induced as well as idiopathic chronic pulmonary 
hypertension
14,127 and acute hypoxic vasoconstriction was completely absent in 
TRPC6
-/- mice, whereas the response to chronic hypoxia was unaltered.
115 
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Figure 7: Activation mechanism for canonical transient receptor potential (TRPC) 
channels.  TRPC channels can be activated in any of three distinct ways. From left: 
Channels sequestered in a vesicular compartment can be translocated to the plasma 
membrane. TRPC channels can be activated by diacylglycerol (DAG), formed as a result of 
activation of phospholipase C (PLC) by a G protein-coupled (G) pathway. Activation of PLC 
leads to the production of inositol-trisphosphate (IP3), which activates the IP3 receptor (IP3R) 
causing release of Ca
2+ from a critical component of the endoplasmic reticulum. This can in 
turn activate TRPC channels through the poorly understood capacitative or store-operated 
pathway (from Putney 2005).
123 
 
The TRPC channels can be activated by several mechanisms (Figure 7). They are 
activated downstream of phospholipase C and are sensitive to diacylglycerol (DAG) 
and inositol-trisphosphate (IP3).
122 Initially TRPC channels were thought to be the 
long sought store-operated channels that account for capacitative Ca
2+ entry. 
However, although a number of studies have reported that store depletion activates 
TRPC channels and that knockout or knockdown of TRPCs reduces store-operated 
Ca
2+ entry.
123 Recent studies have revealed novel components of the capacitative 
Ca
2+ entry, namely the stromal interacting molecule (STIM) and Orai proteins.
128,129 
While STIM1 has been suggested to be the endoplasmatic reticulum Ca
2+ sensor 
protein relaying the signal to the plasma membrane for activation of capacitative Ca
2+ 
entry, Orai1 is reported to be the pore-forming component of store operated 
Ca
2+channels.
130 TRPC channels are however obviously intimately involved in Ca
2+ 
homeostasis as the store-operated and receptor-operated Ca
2+ entry mechanism in 
HEK 293 cells are composed of heteromeric complexes that include TRPCs and Orai 
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proteins that are controlled by STIM1.
131 Another mechanism for the activation of 
TRPC channels involves the regulation of their trafficking and insertion into the 
plasma membrane. It has been reported that TRPC1 translocates to the membrane 
in response to thrombin, TRPC6 and 3 in the presence of carbachol and TRPC4 and 
5 upon activation of the epidermal growth factor receptor.
132-137 Recently our group 
reported that 11,12-EET can affect endothelial Ca
2+-signalling by stimulating the 
intracellular translocation of TRPC6 to caveolae in a cAMP/PKA-dependent 
manner.
69 
 
1.9. 5-Hydroxytryptamine  (serotonin) 
5-Hydroxytrymtamine (5-HT), a potent pulmonary vasoconstrictor, is reported to 
activate TRP channels.
138-140 Several studies have suggested a role for 5-HT in the 
pathogenesis of pulmonary hypertension.
141-144 5-HT is an endogenous vasoactive 
indolamine substance mainly found in enterochromaffin tissue, brain and platelets 
that exerts its multiple physiological effects through diverse receptors. At least 
fourteen different 5-HT receptors, each encoded by a separate gene, are known in 
humans.
145 The latter are divided into seven groups (5-HT1-5HT7) and with exception 
of 5-HT3, they are G protein-coupled receptors. The 5-HT2A receptor couples 
primarily via the G protein Gαq to the activation of PLC and is widely expressed in the 
human vasculature, on the arterial smooth muscle cells that mediate 
vasoconstriction.
145 
Pulmonary vasoconstriction to 5-HT is normally mediated via 5-HT2A receptors.
146 
However, chronic hypoxia is reported to increase the 5-HT-induced pulmonary 
arterial contraction, a response linked to chronic hypoxia-induced upregulation of 5-
HT1B receptors.
146 5-HT has been linked to acute HPV as the molecule itself, 
dexfenfluramine, as well as serotonin transporter inhibition or deletion are reported to 
increase acute HPV.
19-21,147 In addition, appetite suppressant drugs, mainly 
fenfluramines and 5-HT, have been associated with pulmonary arterial 
hypertension
19,144 and the secretion of large amounts of 5-HT from pulmonary 
neuroendocrine cells and neuroepithelial bodies occurs in response to airway 
hypoxia.
148 Recent reports underscored the importance of 5-HTT in pulmonary 
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hypertension by demonstrating that overexpression of the serotonin transporter 
increases chronic hypoxia-induced pulmonary hypertension in mice whereas mice 
lacking the 5-HTT or treated with 5-HTT inhibitors were protected against pulmonary 
hypertension induced by chronic hypoxia.
21,23,149  
 
1.10. Aim of the study 
The aim of the present investigation was to analyse in detail the role of the sEH and 
CYP-derived EETs on acute and chronic HPV, pulmonary artery pressure and 
hypoxia-induced pulmonary vascular remodelling. Therefore a series of specific tools 
to inhibit CYP activity (CYP epoxygenase inhibitors), antagonize the actions of EET 
(14,15-epoxyeicosa-5(Z)-enoic acid), or to prolong their half-life (sEH inhibitors) were 
used. The molecular mechanisms involved in mediating the hypoxia- and 11,12-EET-
induced pulmonary vasoconstriction and pulmonary remodelling described were 
addressed using a combination of cultured pulmonary smooth muscle cells, promoter 
activity assays and genetically modified animals (sEH
-/- mice and TRPC6
-/- mice).  
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2.  Materials and Methods 
2.1. Materials 
Media, enzymes and buffer for cell culture were obtained from GIBCO Life 
Technology (Karlsruhe, Germany), ketamin from Pfizer (Karlsruhe, Germany), 
rompun from Bayer (Leverkusen, Germany) and heparin from Ratiopharm (Ulm, 
Germany). The sEH inhibitors 1-adamantyl-3-cyclohexylurea (ACU) and 1-
adamantan-1-yl-3-{5-[2-(2-ethoxyethoxy)ethoxy]pentyl]}urea (AEPU or IK-950) were 
kindly provided by Bruce D. Hammock (University of California, Davis, USA).
24,150 
The EET antagonist 14,15-epoxyeicosa-5(Z)-enoic acid (14,15-EEZE) and the CYP 
epoxygenase inhibitor MSPPOH were from John R. Falck (University of Texas, 
Dallas, USA).
151 11,12-EET, 14,15-EET, 11,12-DHET and arachidonic acid were 
obtained from Cayman Chemicals (Massy, France), NADPH from Applichem 
(Darmstadt, Germany), U46619 from Alexis (Lörrach, Germany) and Y27632 
dihydrochloride from Tocris (Ellisville, USA). Fenbendazole, 5-HT and all other 
substances were purchased from Sigma (Deisenhofen, Germany). 
 
2.2. Animals 
sEH
-/- mice were obtained from Dr. Frank Gonzalez (National Institutes of Health, 
Bethesda, USA) and crossbred for 8 generations onto the C57BL/6 background. 
TRPC6
-/- and TRPC6
+/- mice, generated as described,
152 were bred by the animal 
facility at the University of Marburg. C57BL/6 mice (6-8 weeks old) were
 purchased 
from Charles River (Sulzfeld, Germany). Tie2-CYP2J2 and Tie2-CYP2C8 mice were 
obtained from Darryl Zeldin (National Institute of Environmental  Health Sciences, 
Durham, USA).  Animals were housed in conditions that conform to the
 Guide for the 
Care and Use of Laboratory Animals published by
  the U.S. National Institutes of 
Health (NIH publication no. 85-23). Both the University Animal Care Committee and 
the Federal Authority for Animal Research at the Regierungspräsidium Darmstadt 
(Hessen, Germany) approved the study protocol (# F28/14). 
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2.3. Isolated  buffer-perfused mouse lung system 
Mice were anesthetised intraperitoneally using ketamin (80 mg/kg body weight) and 
rompun (10 mg/kg body weight) and anticoagulated with heparin (1000 U/kg). 
Animals were then intubated via a tracheostoma and ventilated with room air using a 
positive pressure pump (Mini-Vent Type 845, Hugo Sachs Elektronik, March-
Hugstetten, Germany; 300 µL tidal volume, 90 breath/min and 2 cmH2O positive end-
expiratory pressure). Then mice were transferred to a lung chamber (IL1 Type 839, 
Hugo Sachs Elektronik, March-Hugstetten, Germany). Midsternal thoracotomy was 
followed by insertion of catheters into the pulmonary artery and left atrium. As 
perfusion fluid a Krebs-Henseleit buffer containing 123.1 mmol/L NaCl, 4.4 mmol/L 
KCl, 1.1 mmol/L KH2PO4, 2.5 mmol/L CaCl2, 1.3 mmol/L MgCl2, and 13.5 mmol/L 
glucose as well as hydroxyethyl starch (200/0.5; 50 g/L) was used. Using a peristaltic 
pump (ISM834 MS-4/8, Ismatec, Wertheim-Mondfeld, Germany), buffer perfusion via 
the pulmonary artery was initiated at 4°C and a flow of 0.2 mL/min. In parallel with 
the onset of artificial perfusion, ventilation was changed from room air to a pre-mixed 
gas (21% O2 5.3% CO2, balanced with N2). After rinsing the lungs with 20 mL buffer, 
the perfusion circuit was closed for recirculation and left arterial pressure was set to 
2 mmHg. The flow was slowly increased from 0.2 to 2 mL/min and the entire system 
was heated to 37°C. Pressures in the pulmonary artery, the left atrium and the 
trachea were registered via blood pressure transducers (MLT0670, ADInstruments, 
Bella Vista, Australia) and monitored using a PC coupled bridgeAmp-Powerlab 
system (ML119, ML880, ADInstruments, Bella Vista, Australia). For hypoxic 
ventilation, a gas mixture containing 1% O2, 5.3% CO2, balanced with N2 was used. 
Ten-minute periods of hypoxic ventilation (1% O2) were alternated with 15 min 
normoxic periods (Figure 8). 
For measuring lung weight changes, mouse lungs were removed from the chest in 
deep anaesthesia, artificially ventilated, and perfused blood-free analogous to the 
isolated rabbit lung as described. 
153 
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Figure 8: Isolated buffer-perfused mouse lung system. PAP: pulmonary artery pressure; 
LVP: left ventricle pressure, TP: tracheal pressure. 
 
2.4. Cell  culture 
Rat pulmonary artery smooth muscle cells were isolated as described
154 and cultured 
in M199, supplemented with 10% FCS, penicillin (50 U/mL) and streptomycin (50 
µg/mL).  
 
2.5. RhoA  activation  assay 
Isolated buffer-perfused lungs from wild-type mice were treated with solvent or 11,12-
EET (3 µmol/L, 15 minutes) then snap frozen in liquid N2. Lungs were then 
  24Materials and Methods 
homogenised and RhoA activity was determined using a specific G-LISA assay 
(Cytoskeleton, Denver, USA). 
 
2.6. Protein  isolation 
Myosin light chain (MLC) 20 and α-smooth muscle actin: Rat pulmonary artery 
smooth muscle cells were maintained under normoxic conditions, treated with 
U46619 (1 µmol/L, 10 minutes) or exposed to hypoxia for 30 minutes. Cells were 
then immediately treated with trichloroacetic
 acid (15% w/v) and frozen in liquid N2. 
After 30 minutes on ice, the suspension
 was centrifuged (4°C, 14000g, 30 minutes), 
and the pellet washed 3 times with water-saturated
 diethyl ether. Air-dried samples 
were solubilised in an ice cold Triton
  X-100 lysis buffer for 10 minutes, then 
centrifuged (4°C, 10000g, 10 minutes) and the protein concentration of the 
supernatant was determined (Bradford 1976). 
CYP2C11 and sEH: Cells were washed with PBS and solubilised using ice cold 
Triton
 X-100 lysis buffer for 10 minutes, then centrifuged (4°C, 10000g, 10 minutes) 
and the protein concentration of the supernatant was determined (Bradford 1976). 
 
2.7. Western  blot  analysis 
Protein samples were separated via electrophoresis on a denaturating 
polyacrylamide gel in a buffer solution consisting of 190 mmol/L glycine, 0.1% SDS 
and 25 mmol/L TRIS-HCl and transferred on a nitrocellulose membrane (60 minutes 
at 250 mA). Afterwards the membranes were transferred to a solution of 3% bovine 
serum albumin in TRIS buffered saline with Tween (TBST, consisting of 50 mmol/L 
TRIS/HCl, pH 7.5, 150 mmol/L NaCl, 0.3% Tween-20) to block unspecific binding 
sites on the membrane.  After incubation with the according primary antibody 
overnight, multiple washing steps with TBST and another blocking step, membranes 
were incubated with a horseradish peroxidase conjugated secondary antibody 
followed by repeated washing.  Proteins were finally detected by applying an x-ray 
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film on the membrane that was subjected to a chemiluminescence reaction via the 
‘Enhanced Chemiluminescence’ system (Amersham/Pharmacia). 
The utilised antibodies were directed against CYP2C11 (Acris, Hiddenhausen, 
Germany), sEH (Prof. Michael Arand, Zürich, Switzerland), the phosphorylated form 
of the myosin light chain 20 (Cell signalling, Danvers, USA) and α-smooth muscle 
actin (Sigma; Saint Louis, USA). 
 
2.8. Immunohistochemistry 
sEH: Mice were euthanised by an intraperitoneal overdose of pentobarbital sodium. 
After intubation, a midsternal thoracotomy was performed, catheters were placed in 
the pulmonary artery and the left atrium, and the vasculature was flushed with 20 mL 
saline at a pulmonary artery pressure of 22 cmH2O and a tracheal pressure of 12 
cmH2O. Thereafter, the pulmonary vasculature was perfused with Zamboni´s fixative 
for 30 minutes at the same pressures. After ligation of the pulmonary artery, veins, 
and the trachea, lungs were removed and placed in the Zamboni´s fixative for a 
further 6 hours at room temperature, followed by incubation in phosphate buffer (0.1 
mol/L, 12 hours, 4°C). Tissues were then dehydrated and infiltrated with paraffin in 
an automated vacuum tissue processor (Leica TP1050, Bensheim, Germany). After 
deparaffinisation and rehydration of 3 µm sections, endogenous peroxidase was 
blocked in 3% hydrogen peroxide. Slides were incubated with trypsin (Digest All, 
Zytomed, Berlin, Germany) for 10 minutes for retrieval of the antigen and unspecific 
binding sites were blocked using horse serum (Alexis, Grünberg, Germany). The 
sections were incubated overnight (4°C) with a polyclonal sEH antibody (dilution 
1:2000) raised against a recombinant murine sEH produced in the baculovirus 
expression system and then purified to apparent homogeneity by affinity 
chromatography. The ImmPRESS anti-rabbit IgG Peroxidase kit (Vector/Linaris, 
Wertheim-Bettingen, Germany) was then used according to the manufacturer’s 
protocol and the sEH visualised using the Nova Red chromogen kit for horseradish 
peroxidase (Vector, Linaris, Wertheim-Bettingen, Germany). Nuclear counterstaining 
was performed with hematoxylin (Zytomed, Berlin, Germany). 
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TRPC6: Translocation of the TRPC6 channel was assessed in cultured rat pulmonary 
smooth muscle cells infected with an adenovirus encoding a V5-tagged TRPC6 
fusion protein (TRPC6-V5) as described.
69 Following stimulation, samples were fixed 
(4% paraformaldehyde in PBS), permeabilised with Triton X-100 and incubated with 
phalloidin (Molecular Probes, Leiden, Netherlands) and specific antibodies to V5 
(Invitrogen) or caveolin-1 (BD Biosciences). The preparations were mounted and 
viewed using a confocal microscope (LSM 510 META, Zeiss). 
 
2.9.  Preparation of lung microsomes 
Lungs were minced and homogenised in 5 vol. of ice-cold 50 mM Tris/HCl buffer (pH 
7.4) containing 0.25 M sucrose, 150 mM potassium chloride, 2 mM EDTA, 2 mM 
dithiothreitol (DTT), 1 µmol/L FAD and FMN, and 0.25 mM PMSF in a motor-driven 
homogeniser. After differential centrifugation (10 minutes, 1000 g; 20 minutes, 10000 
g; 90 minutes, 100000 g), the microsomes were suspended and homogenized in 50 
mM Tris/HCl buffer (pH 7.7) containing 20% (v/v) glycerol, 5 mM EDTA and 1 mM 
DTT. Aliquots were snap-frozen in liquid nitrogen and stored at -80 °C. 
 
2.10. Eicosanoid measurements by LC-MS/MS 
Lung microsomes were prepared as described above. Microsomal protein (50 µg) 
was incubated in 100 µL of potassium phosphate buffer (100 mmol/L, pH 7.2) 
containing arachidonic acid (10 µmol/L) in the absence or presence of fenbendazole 
(100 µmol/L) and MSPPOH (10 µmol/L) for 15 minutes. To determine hypoxia-
induced EET generation, microsomal proteins were incubated with either an hypoxic 
(1% O2) or normoxic Krebs-Henseleit buffer containing arachidonic acid (10 µmol/L) 
for 10 minutes. Reactions were started by addition of NADPH (1 mmol/L final 
concentration) and terminated after 20 minutes by placing on ice. The reaction 
products were extracted twice using ethyl acetate, evaporated under nitrogen, 
resuspended in methanol/water (v/v, 1:1). To determine acute hypoxia-induced EET 
generation in intact cells, rat PASMCs were incubated with arachidonic acid (100 
nmol/L). After 5 hours, cells were washed and after an additional hour PASMCs were 
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incubated with either a hypoxic (1% O2) or normoxic cell culture medium for 10 
minutes. Reactions were terminated by placing them on ice. Cells were harvested by 
scraping and reaction products were extracted as described.
155 The activity of the 
sEH was determined using cytosolic cell lysates generated as described.
156 
Reactions were performed at 37°C for 20 minutes in 100 μl of 100 mmol/L potassium 
phosphate buffer (pH 7.2) containing 5 μg protein. Reactions were started by the 
addition of 14,15-EET (10 μmol/L) and stopped on ice and immediately extracted 
twice with ethyl acetate (0.7 mL). One tenth of the sample was spiked with a 
deuterated internal standard (14,15-EET-d8). After evaporation of the solvent in a 
vacuum block under a gentle stream of nitrogen the residues were reconstituted with 
50 µL of methanol/water (v/v, 1:1). Eicosanoid profiles were determined with a Sciex 
API4000 mass spectrometer operating in multiple reaction monitoring (MRM) mode 
as described.
155 
 
2.11. Chronic hypoxia 
For chronic hypoxia exposure, mice were kept under normobaric hypoxia (10% O2) in 
a ventilated chamber for up to 21 days. The level of hypoxia was held constant by an 
autoregulatory control unit (BioSpherix, Lacona, USA) supplying either nitrogen or 
oxygen and CO2 was continuously removed by soda lime. Cages were opened once 
per day for cleaning as well as for food and water supply. Control mice were exposed 
to normoxia (21% O2) under identical conditions for 21 days. 
 
2.12. RNA isolation and reverse transcriptase polymerase chain 
reaction 
Total RNA from murine wild-type lungs was isolated as described.
157 Homogenised 
samples were incubated in Tri
®Reagenz at room temperature to permit the complete 
dissociation of the nucleoprotein complex. Afterwards the solution containing RNA as 
well as DNA was mixed with chloroform (20% v/v). Samples were shaken vigorously 
by hand for 15 seconds and incubated at room temperature for 2 to 3 minutes. The 
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aqueous and organic phases were separated by centrifugation for 30 minutes at 
12000g. The aqueous phase containing the RNA was transferred to a fresh tube and 
the nucleic acid was precipitated by adding an equal volume isopropanol (100%). 
Thereafter samples were incubated at room temperature for another 10 minutes, 
centrifuged, washed with ethanol (75%) and diluted in RNase-free water. RNA 
concentration was determined by photometric measurement at 260 nm. 
For the reverse transcriptase-polymerase chain reaction 1 µg RNA was used.   
Incubation with reaction buffer (Invitrogen, Karlsruhe, Germany), desoxynucleosid-5’-
triphophate (175 µmol/L of dATP, dCTP, dGTP and dTTP), dithiothreitol (1 mmol/L), 
random hexanucleotides and reverse transcriptase (Superscript III, Invitrogen, 
Karlsruhe, Germany) for 60 minutes at 50ºC resulted in cDNA-synthesis. To avoid 
false positive results by contamination a negative control without reverse 
transcriptase was used.   
For the amplification of cDNA during the PCR (15 minutes at 95°C followed by 40 
cycles à 30 seconds at 95°C, 1 minute at 60°C and 30 seconds at 72°C in a Mx4000 
multiplex quantitative PCR system (Stratagene, Heidelberg, Germany)) the following 
primers were used:  
sEH:    forward  5’-  AAGTAATCTGAAGCCAGCCCGT-3’ 
sEH:    reverse  5’-  AGAGCCATGTTCCACACCATCA-3’ 
To ensure that equal amounts of cDNA were used, 18S RNA was amplified by qPCR 
(Assay on Demand, Applied Biosystems, Darmstadt, Germany) and the amount of 
cDNA in the samples was calculated on the basis of the amplification of a serial 
dilution of a plasmid (sEH) or the serial dilution of the cDNA (18S RNA). The sEH 
levels were normalised to that of 18S. At least two RT reactions were performed 
using each RNA preparation and at least two PCR reactions were performed with 
each cDNA sample.  
 
2.13. sEH promoter activity 
HEK 293 cells were transiently co-transfected with the 4 kb sEH promoter or the 1.5 
kb sEH promoter (Kindly provided by D. Hammock) together with a LacZ construct. 
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After 24 h, the cells were lysed, and luciferase activity was assayed according to the 
manufacturers protocol (Promega, Mannheim, Germany). The values were corrected 
for transfection efficiency by measuring β-galactosidase activity (Tropix, Bedford, 
MA). 
 
2.14. Hematocrit and right heart hypertrophy determination 
Prior to artificial perfusion, an aliquot of blood was drawn from the left atrial catheter 
and spun in an Adams autocrit centrifuge (Clay Adams, Parsippany, USA) for 
hematocrit determination. In some animals, the right ventricle was dissected from the 
left ventricle and septum, dried and weighed to obtain the right to left ventricle plus 
septum ratio  
 
2.15. Vessel morphometry 
Morphometric analysis of the pulmonary vasculature was performed as described.
158 
Briefly, for determination of the degree of muscularisation, vessels were classified as 
nonmuscular (no smooth muscle cells detectable with α-actin staining), partially 
muscularised (at least one smooth muscle cell up to 75% circumference with α-actin 
staining), and fully muscularised (>75% of circumference with α-actin staining) This 
analysis was performed for at least 80 small vessels (20–70 µm diameter), 15 
medium vessels (>70–150 µm diameter) and 5 large vessels (>150–1000 µm 
diameter) of each section. One section from each, the left upper, right upper, and left 
lower lobe was analysed. All morphometric analysis were done in a blinded fashion. 
 
2.16. Statistical Analysis 
Data are expressed as mean±SEM and statistical evaluation
 was performed using 
Student’s t-test for unpaired data or 1-way
 ANOVA followed by a Bonferroni t-test 
where appropriate. Values
 of P<0.05 were considered statistically significant. 
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3. Results 
3.1.  Effect of 11,12-EET on pulmonary arterial pressure 
In lungs from wild-type mice, the application of 11,12-EET (10 nmol/L to 3 µmol/L) to 
the pulmonary perfusate rapidly and concentration-dependently increased pulmonary 
artery pressure (Figure 9) while 14,15-EET and the solvent DMSO (0.3 ‰) were 
without significant effect (Figure 9B). 11,12-DHET also failed to affect pulmonary 
artery pressure (Figure 9B). 
 
2 min
A B 
-8 -7 -6 -5
0
1
2
3
**
***
*** 11,12-EET
Sol
14,15-EET
11,12-DHET
[EET] log mol/L
Δ
 
P
A
P
 
(
m
m
 
H
g
)
7 
8 
9 
10 
11 
-8 -7.5 
-7 
-6,5
-6
-5.5
[11,12-EET] log M 
P
A
P
 
(
m
m
 
H
g
)
 
 
Figure 9: Effect of 11,12-EET, 11,12-DHET and 14,15-EET on pulmonary arterial 
pressure in lungs from wild-type mice. (A) Original tracing showing the effect of 11,12-
EET on pulmonary arterial pressure in lungs from wild-type mice. (B) Effect of 11,12-EET (10 
nmol/L to 3 µmol/L), 11,12-DHET EET (10 nmol/L to 3 µmol/L) and 14,15-EET (10 nmol/L to 
3 µmol/L) versus their solvent (Sol, 0.3 ‰ DMSO) on pulmonary arterial pressure in lungs 
from wild-type mice. The graph summarises data obtained using 4-6 animals per group; 
**P<0.01, ***P<0.001 versus solvent. 
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3.2.  Effect of sEH and CYP epoxygenase inhibition on acute 
hypoxic pulmonary vasoconstriction in isolated buffer-
perfused mouse lungs 
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Figure 10: Effect of sEH and CYP inhibition on hypoxia-induced vasoconstriction in 
the isolated perfused mouse lung. (A) Original tracings showing the effect of acute 
hypoxia (1% O2) on pulmonary arterial pressure before and after administration of solvent or 
the soluble epoxide hydrolase inhibitor, ACU (3 µmol/L). (B) Hypoxic pulmonary 
vasoconstriction in lungs from mice treated with solvent (CTL), ACU or AEPU (3 µmol/L). The 
bar graph summarises data obtained in 5-6 independent experiments; *P<0.05, **P<0.01 
versus solvent. 
 
In lungs from wild-type mice hypoxic ventilation (FiO2 = 0.01) resulted in an acute 
increase in pulmonary artery pressure (Figure 10A) that is attributable to acute HPV. 
Repeated stimulation (up to five times) resulted in quantitatively similar responses. 
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To analyse the role of endogenous EETs in the pulmonary circulation, lungs from 
wild-type mice were incubated with sEH inhibitors, thereby preventing the metabolism 
of EETs to their less active DHETs and enhancing endogenous EET levels. 
Following application of the sEH inhibitor, ACU, to the pulmonary perfusate, the 
acute hypoxic vasoconstrictor response was significantly augmented (Figure 10A&B). 
A similar response was observed using a second sEH inhibitor, AEPU,
24 which has a 
comparable potency but markedly different physical properties (Figure 10B).  
Previous reports revealed that sEH activity is greater in male than in female mice and 
rats and that castration decreased sEH activity and expression; a phenomenon 
restored by testosterone supplementation.
99,100 Moreover, as female animals 
demonstrated a more pronounced response to sEH inhibition in our previous study
24 
we assessed the acute HPV response in castrated, ovarectomised and sham 
operated male and female C57BL/6 mice. In contrast to previous observations in 
Swiss Webster mice, HPV did not differ between the different subgroups and 
inhibition of the sEH potentiated the acute HPV to the same level in all of the groups 
analysed (Figure 11). 
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Figure 11: Effect of gender on acute hypoxic pulmonary vasoconstriction in the 
isolated mouse lung. Hypoxic pulmonary vasoconstriction in lungs from female sham-
operated (fem) and ovarectomised (ovar) mice, as well as male sham-operated and 
castrated (castr) mice treated with solvent (CTL) or ACU (3 µmol/L). The bar graph 
summarises data obtained in 4-6 independent experiments; *P<0.05, ***P<0.001 versus the 
corresponding solvent treated group. 
 
  33Results 
To determine whether or not CYP-derived EETs are involved in acute hypoxic 
pulmonary vasoconstriction responses experiments were re-assessed in animals 
treated with fenbendazole (4% in chow) for two weeks. CYP inhibition by 
fenbendazole was demonstrated in murine lung microsomes by determining the 
conversion of arachidonic acid to EET. Fenbendazole was equally effective as the 
epoxygenase inhibitor MSPPOH in attenuating the generation of 11,12- and 14,15-
EET without affecting the generation of either 5,6- or 8,9-EET (Figure 12A). 
Treatment of mice with fenbendazole was without significant effect on the magnitude 
of acute HPV (Figure 12B) but significantly attenuated the potentiation of 
vasoconstriction induced by sEH inhibition (Figure 12B). 
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Figure 12: Effect of fenbendazole on CYP epoxygenase activity and acute hypoxic 
vasoconstriction.  (A) Comparison of the effects of the CYP epoxygenase inhibitors 
MSPPOH and fenbendazole on arachidonic acid epoxide production in microsomes prepared 
from murine lungs. Epoxygenase activity was assessed by monitoring EET production 
following the addition of arachidonic acid (AA, 10 µmol/L, 20 minutes). Experiments were 
performed in the presence of either solvent (Sol), MSPPOH (MS, 10 µmol/L) or fenbendazole 
(Fen, 100 µmol/L). The graph summarises data obtained in 4 independent experiments; *P 
<0.05 versus AA + solvent. Reaction mixtures lacking AA served as a negative control. (B) 
Effect of fenbendazole (Fen; 4%, 14 days) on acute hypoxic pulmonary vasoconstriction. The 
bar graphs summarise data obtained in 5-6 independent experiments; ***P<0.001 versus 
solvent; §P<0.05 versus ACU/CTL. 
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In a second protocol the consequences of acute CYP epoxygenase inhibition and 
EET antagonism on hypoxic vasoconstriction were tested. MSPPOH and 14,15-
EEZE had only a marginal effect on their own but both substances completely 
prevented the increased constriction induced by sEH inhibition (Figure 13). 
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Figure 13: Effect of sEH and CYP inhibition on hypoxia-induced vasoconstriction in 
the isolated perfused mouse lung. Hypoxic pulmonary vasoconstriction was assessed in 
the presence of solvent (Sol), MSPPOH (MS, 10 µmol/L), or 14,15-EEZE (EEZE, 10 µmol/L) 
and in the absence and presence of ACU (3 µmol/L). The bar graph summarises data 
obtained in 3-6 independent experiments; **P<0.01 versus solvent; §<0.05, §§P<0.01 versus 
ACU/CTL. 
 
3.3.  Acute hypoxic pulmonary vasoconstriction in lungs from 
sEH
-/- mice 
Although the sEH is expressed in the carotid artery endothelium,
104 this is not the 
case in the lung where the enzyme was selectively expressed in vascular smooth 
muscle cells (Figure 14A). No sEH was detected in lungs removed from sEH
-/- mice 
(Figure 14A). 
Next the acute HPV response in lungs from wild-type mice and lungs from sEH
-/- 
mice was assessed. As before, in lungs from wild-type mice, sEH inhibition enhanced 
the acute hypoxic vasoconstriction (Figure 14B). Lungs from sEH
-/- mice displayed 
significantly enhanced hypoxic vasoconstriction responses compared to solvent 
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treated lungs from wild-type mice (Figure 14B). As expected, the sEH inhibitor had 
no effect on acute hypoxic vasoconstriction in lungs from sEH
-/- mice (Figure 14B). 
However CYP epoxygenase inhibition and EET antagonism returned hypoxic 
responses to levels observed in lungs from wild-type animals (Figure 14B), indicating 
that the enhanced response to hypoxia was dependent on the activation of a CYP 
epoxygenase and the generation of an EET. 
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Figure 14: Hypoxic pulmonary vasoconstriction in lungs from sEH
-/- mice. (A) 
Immunohistochemical analysis showing the expression of the sEH (in brown) in lungs from 
wild-type (WT) and sEH
-/- mice. (B) Hypoxic pulmonary vasoconstriction in lungs of WT and 
sEH
-/- mice treated with solvent (Sol) or ACU (3 µmol/L) in the absence and presence of 
MSPPOH (MS, 10 µmol/L) or 14,15-EEZE (EEZE, 10 µmol/L). The bar graph summarises 
data from 3-6 independent experiments; *P<0.05 versus Sol WT; §P<0.05 versus Sol sEH
-/-. 
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Moreover, in microsomes prepared from the lungs of wild-type mice, hypoxia (10 
minutes) elicited a significant increase in EET production. As expected, EET levels in 
microsomes from the lungs of sEH
-/- mice were greater than those detected in 
samples from wild-type animals and were also increased in response to hypoxia 
(Figure 15A-C). In intact rat PASMCs hypoxia (10 minutes) significantly increased 
11,12-EET production (Figure 15D) but had no effect on 8,9-EET and 14,15-EET 
generation (data not shown). 
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Figure 15: Effect of hypoxia on EET levels in murine lung microsomes and rat 
PASMCs. Microsomal protein from wild-type (WT) and sEH
-/- mice (A-C) or rat PASMCs (D) 
were either maintained under normoxic conditions (21% O2) or exposed to 1% O2 for 10 
minutes. EET levels were determined using LC-MS/MS. The bar graphs summarise data 
from 4-5 independent experiments; *P<0.05, **P<0.01 versus normoxic wild-type 
microsomes; *P<0.05 versus normoxic PASMCs. 
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3.4. Effect  of  CYP2C8  and  CYP2J2 overexpression on acute 
hypoxic pulmonary vasoconstriction 
In the systemic circulation the activation
 of CYP epoxygenases in endothelial cells is 
an important step
 in the NO and PGI2-independent vasodilation of several vascular 
beds.
40,159-161 An initial step in such EDHF-mediated responses is endothelial cell 
hyperpolarisation and recently, overexpression of CYP2C9 in human umbilical vein 
endothelial cells has been reported to potentiate bradykinin-induced Ca
2+ influx and 
hyperpolarisation.
69 Given this modulatory role of CYP overexpression on the 
vascular cells and the above-demonstrated involvement of CYP epoxygenase-
derived products in hypoxia-induced vasoconstriction, the acute HPV response was 
assessed in lungs from mice overexpressing CYP2C8 or CYP2J2 in the endothelium 
(i.e. under the control of the Tie-2 promotor) and their corresponding wild-type 
littermates. 
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Figure 16: Effect of endothelial specific (A) CYP2C8 and (B) CYP2J2 overexpression 
on acute hypoxic pulmonary vasoconstriction. The acute hypoxic pulmonary 
vasoconstriction response was assessed in lungs from CYP2C8 (2C8) or CYP2J2 (2J2) 
overexpressing mice and their corresponding wild-type littermates (WT). The graphs 
summarise data obtained in 4 independent experiments; *P<0.05 versus WT. 
 
Acute HPV was similar in lungs from wild-type, CYP2C8 and CYP2J2 mice (Figure 
16). Inhibition of the sEH enhanced the acute HPV in lungs from wild-type littermates 
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(Figure 16) while in lungs from CYP2C8 and CYP2J2 overexpressing animals the 
ACU-dependent increase in hypoxic vasoconstriction was less pronounced (Figure 
16). Although the effects failed to reach statistical significance, these data suggest 
that endothelium-derived EETs attenuate pulmonary vasoconstriction and that the 
hypoxia-sensitive CYP enzyme that contributes to HPV most probably is localised in 
pulmonary artery smooth muscle cells. 
 
3.5.  Effect of hypoxia and 11,12-EET on the RhoA/Rho kinase 
pathway 
Hypoxia-induced pulmonary vasoconstriction has been attributed to activation of the 
Rho kinase.
162,163 Given that the contraction elicited by the CYP-derived eicosanoid, 
20-HETE, in the systemic circulation is linked to the Rho kinase-dependent 
phosphorylation MLC
70 the effects of hypoxia, ACU and 11,12-EET on Rho kinase 
activity were compared using rat PASMCs and isolated lungs. For these analysis 
PASMCs were used as a functional tool as they expressed both, CYP2C11 and sEH 
(Figure 17) 
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Figure 17: Representative Western blots demonstrating the expression of CYP2C11 
and the sEH in rat pulmonary artery smooth muscle cells (PASMC). PC = positive 
control i.e. in the case of CYP2C11 CYP2C11-supersomes and the recombinant human 
protein in the case of the sEH.  
 
In pulmonary artery smooth muscle cells, hypoxia stimulated the phosphorylation of 
MLC-20, an effect that was significantly potentiated by ACU and largely prevented by 
the Rho kinase inhibitor Y27632 (Figure 18A). The exogenous application of 11,12-
EET had no significant effect on MLC-20 phosphorylation (not shown) but increased 
Rho kinase activity (measured by G-LISA) in the isolated perfused lung (Figure 18B). 
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Figure 18: Effect of hypoxia, ACU and 11,12-EET on Rho kinase activity. 
(A)  Representative Western blots and corresponding bar graph showing the effects of 
hypoxia on the phosphorylation of MLC-20 (p-MLC) in rat pulmonary artery smooth muscle 
cells. Experiments were performed in the absence or presence of ACU (3 µmol/L) and 
Y27632 (Y27, 10 µmol/L); cells were stimulated with U46619 (1 µmol/L) as positive control. 
(B) Effect of 11,12-EET (3 µmol/L, 15 minutes) on RhoA activity (measured by G-LISA) in 
isolated murine lungs. The graphs summarise data obtained in 4 independent experiments; 
*P<0.05, **P<0.01, ***P<0.001 versus CTL or solvent. 
 
In a next step the effect of Rho kinase inhibition on the 11,12-EET-induced increase 
in pulmonary  artery pressure and ACU-induced increases in HPV were assessed. In 
lungs from wild-type mice the increase in pulmonary artery pressure elicited by 
11,12-EET was significantly inhibited by Y27632, a Rho kinase inhibitor (Figure 19A). 
Moreover, 11,12-EET enhanced the acute hypoxic pulmonary vasoconstriction 
response to same level as ACU and both effects were sensitive to Rho kinase 
inhibition (Figure 19B). 
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Figure 19: Sensitivity of the effects of 11,12-EET and ACU to Rho kinase inhibition. 
Effect of the Rho kinase inhibitor Y27632 (1 µmol/L) on (A) the 11,12-EET-induced increase 
in pulmonary artery pressure and (B) the 11,12-EET (3 µmol/L) or ACU-induced potentiation 
in hypoxic vasoconstriction in lungs from wild-type mice. The graphs summarise data 
obtained in 4-5 independent experiments; *P<0.05, **P<0.01, ***P<0.001 versus CTL or 
solvent; §P<0.05 versus EET alone and §§P<0.01 versus ACU alone. 
 
3.6.  Role of the 5-HT2A receptor in 11,12-EET-induced contraction 
and acute hypoxic pulmonary vasoconstriction 
As 5-HT is undoubtedly a modulator of HPV
164 and the 5-HT2A receptor is mainly 
expressed in pulmonary artery smooth muscle cells
145 we assed the role of the 5-
HT2A receptor on the ACU-dependent increase in HPV and the EET-induced 
contraction in murine lungs.  
In lungs from wild-type mice, preincubation with ketanserin or ritanserin (5-HT2A 
receptor inhibitors) abrogated the effect of sEH inhibition on HPV (Figure 20A). 
Furthermore, in lungs from wild-type mice, ritanserin slightly decreased the basal 
HPV and significantly inhibited the 11,12-EET-induced increase in acute HPV (Figure 
20B). 
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Figure 20: Effect of 5-HT2A receptor inhibition on the ACU-induced or 11,12-EET-
induced potentiation of hypoxic vasoconstriction. (A) Hypoxic pulmonary 
vasoconstriction was assessed in the presence of solvent (Sol), ketanserin (Ket1, 1 µmol/L or 
Ket2, 10 nmol/L), or ritanserin (Rit, 10 nmol/L) and in the absence and presence of ACU (3 
µmol/L). (B) Effect of ritanserin (Rit, 10 nmol/L) on the 11,12-EET-induced potentiation in 
hypoxic vasoconstriction in lungs from wild-type mice. The graphs summarise data obtained 
in 3-5 independent experiments *P<0.05, **P<0.01 versus Sol alone; §P<0.05, §§P<0.01 
versus ACU alone or Sol + EET.  
 
Given that sEH inhibition enhanced the acute HPV, through EETs, and that this effect 
was sensitive to 5-HT2A receptor antagonism, the effect of 5-HT2A receptor inhibition 
on 11,12-EET-induced increase in pulmonary artery pressure was assessed. Thirty 
minutes preincubation of murine lungs with ritanserin significantly shifted the 11,12-
EET concentration-response curve to right (Figure 21). 
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Figure 21: Effect of 5-HT2A 
receptor inhibition on the 11,12-
EET-induced increase in
pulmonary artery pressure.
Lungs from wild-type mice were 
treated with solvent or ritanserin 
(10 nmol/L) and the 11,12-EET 
concentration-response curve was 
assessed. The graph summarises 
data obtained in 3-4 independent 
experiments; ***P<0.001 versus 
solvent. 
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3.7. Effect  of  hypoxic  preconditioning on the 5-hydroxytryptamine-
induced pulmonary vasoconstriction 
5-HT is known to be a potent pulmonary vasoconstrictor and others recently 
demonstrated that chronic hypoxia enhances the 5-HT response in murine 
pulmonary resistance arteries.
165  Moreover, in rat PASMCs 5-HT induced a [Ca
2+]i 
ncrease that was sensitive to CYP-epoxygenase inhibition.
140 Therefore,the effects of 
hypoxia and sEH inhibition or sEH deletion on the 5-HT dose response curve were 
assessed. 
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Figure 22: Effect of 5-HT on pulmonary artery pressure. (A) Effect of 5-HT on pulmonary 
artery pressure of lungs from wild-type mice in the presence or absence of ACU and on 
lungs from sEH
-/- mice. (B) Effect of hypoxic preconditioning (two hypoxic periods prior the 5-
HT concentration-response curve) on pulmonary artery pressures of wild-type lungs and 
sEH
-/- lungs. The graphs summarise data obtained in 3-5 independent experiments. *P<0.05, 
**P<0.01,***P<0.001 versus CTL. 
 
In lungs from wild-type and sEH
-/- mice, 5-HT concentration-dependently increased 
pulmonary artery pressure (Figure 22A). sEH inhibition had no effect on the 5-HT 
concentration-response curve to 5-HT (Figure 22A) and the EC50 values to 5-HT 
were similar in all three groups (LogEC50 in mol/L, CTL: -5.96±0.08; ACU: -
6.13±0.12; sEH
-/-: -6.32±0.2). Interestingly, in lungs from wild-type and sEH
-/- mice, 
hypoxic preconditioning (two hyoxic periods prior to the 5-HT concentration-response 
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curve) enhanced the sensitivity to 5-HT (LogEC50 in mol/L, -6.2±0.18; Figure 22B). 
ACU further increased the hypoxia-induced 5-HT-hypersensitivity in wild-type mice 
(LogEC50 in mol/L, -5.72±0.34). After hypoxic preconditioning, the sEH
-/- lungs 
displayed a striking leftward shift in the 5-HT response (LogEC50 in mol/L, 
-7.46±0.38; Figure 22B). 
 
3.8.  Identification of TRPC6 as an effector of 11,12-EET-induced 
pulmonary vasoconstriction 
TRP channels are known to be activated by Gαq-coupled receptors, such as the 5-
HT2A receptor.
166 Because TRPC6 has been linked to HPV,
115 and our group recently 
reported that 11,12-EET can affect endothelial Ca
2+-signalling by stimulating the 
intracellular translocation of TRPC6 to caveolae,
69 the effect of 11,12-EET on 
pulmonary arterial pressure and acute HPV in lungs from TRPC6
-/- mice and their 
heterozygous (TRPC6
+/-) littermates was analysed. 
In lungs from control (TRPC6
+/-) mice, acute hypoxia elicited a vasoconstriction that 
was potentiated by 11,12-EET (Figure 23A). Moreover, 11,12-EET (10 nmol/L to 3 
µmol/L) elicited a concentration-dependent increase in pulmonary artery pressure 
that was similar to that observed in wild-type mice (Figure 23B). Hypoxia failed to 
elicit an acute increase in pulmonary pressure in lungs from TRPC6
-/- mice (Figure 
23A). Moreover, in the latter animals, 11,12-EET failed to significantly potentiate the 
response to hypoxia or elicit an increase in pulmonary artery pressure on its own 
(Figure 23).  
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Figure 23: Identification of TRPC6 as an effector of 11,12-EET-induced pulmonary 
vasoconstriction.  (A) Hypoxic pulmonary vasoconstriction in buffer-perfused lungs from 
TRPC6
+/- and TRPC6
-/- mice before (CTL) and after treatment with 11,12-EET (EET, 3 
µmol/L). (B) Concentration-dependent effect of 11,12-EET on pulmonary arterial pressure in 
lungs isolated from TRPC6
+/- and TRPC6
-/- mice. The graphs summarise data obtained in 5-6 
independent experiments; *P<0.05 versus control and §§ P<0.001 versus TRPC6
+/- + 11,12-
EET. 
 
To assess the consequences of 11,12-EET on the intracellular localisation of TRPC6 
a TrpC6-V5 fusion protein, in a double cassette together with GFP, was 
overexpressed in rat PASMCs. In cells maintained under basal conditions, the 
TRPC6-V5 was localised to the peri-nuclear Golgi apparatus as was the majority of 
the GFP signal (Figure 24A-C).  
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Figure 24: Effect of 11,12-EET or hypoxia on TRPC6-V5 translocation. Rat pulmonary 
smooth muscle cells were infected with TrpC6-V5 adenoviruses 24 hours prior to stimulation 
with (A) 11,12-EET (3 µmol/L, 5 minutes) in the absence and presence of ritanserin (10 
nmol/L) or (B) hypoxia (1% O2, 5 minutes) in the absence and presence of 14,15-EEZE 
(EEZE, 10 µmol/L). (A&B) Green=GFP, red=V5, blue=phalloidin. (C) Effect of 11,12-EET (3 
µmol/L, 5 minutes) and hypoxia (1% O2, 5 minutes) on the translocation of TrpC6-V5 to 
caveolae. Green=GFP, red=V5, blue=caveolin-1. Identical results were obtained in three 
additional experiments, each using a different cell batch. 
 
Following the application of 11,12-EET (3 µmol/L, 5 minutes) the channel 
translocated to the plasma membrane (Figure 24A) more specifically to membrane 
domains enriched with the caveolae marker, caveolin-1 (Figure 24C). This effect was 
prevented by the 5-HT2A receptor inhibitor ritanserin (Figure 24A) whereas the Rho 
kinase inhibitor Y27632 had no effect (data not shown). Exposure of cells to 1% O2 
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(5 minutes) also stimulated the intracellular translocation of TRPC6-V5 to caveolae 
(Figure 24B&C), an effect not observed in cells pretreated with the EET antagonist, 
14,15-EEZE (Figure 24B). 
EETs have been suggested to increase lung vascular permeability by the activation 
of endothelial TRPV4 channels.
167 To exclude that the effects of exogenous (and 
potentially endogenous) 11,12-EET were in part attributable to interstitial/alveolar 
oedema formation causing a “secondary” HPV, EET-induced changes in lung 
permeability were assessed by measuring lung weight changes. However, although 
14,15-EET has been linked to permeability changes, we found no effect of 11,12-
EET on permeability in the isolated mouse lung (Figure 25). 
 
Figure 25: Effect of 11,12-EET on lung weight 
gain.  11,12-EET- (EET, 10 nmol/L to 3 µmol/L, 
~30 minutes) and solvent-induced (Sol, 0.3 ‰ 
DMSO) changes in lung permeability by 
maintaining lung weight. The graph summarises 
data obtained in 5 animals. 
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3.9. Effect  of  chronic  hypoxia on hematocrit, right heart 
hypertrophy and pulmonary vascular resistance  
Chronic exposure to hypoxia is a major stimulus for the development of pulmonary 
hypertension and elevated pulmonary vascular resistance, which is associated with 
architectural remodelling. Chronic hypoxia in human subjects living at high altitude 
induces erythropoiesis,
168,169 an effect that was also observed following arachidonic 
acid administration.
170 Excessive erythrocytosis is known to be associated with a high 
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risk of cardiovascular complications and has been suggested to contribute to the 
development of pulmonary hypertension.
171,172 
When kept in normoxic conditions, hematocrit levels of wild-type and sEH
-/- mice did 
not differ (Figure 26). However, when exposed to chronic hypoxia (10% O2) for 3 
weeks, the hematocrit increased in wild-type mice and sEH
-/- mice compared to the 
respective normoxic control (Figure 26). In sEH
-/- mice however, the hematocrit was 
significantly greater than that of wild-type mice following chronic exposure to hypoxia 
(Figure 26).  
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Figure 26: Effect of chronic hypoxia on the hematocrit in wild-type and sEH
-/- mice. 
Hematocrit is given for wild-type (WT) as well as for sEH
-/- mice either kept in normoxic 
conditions (21% O2) or exposed to chronic hypoxia (10% O2) for 21 days. The graph 
summarises data obtained in 5-6 animals per group; ***P<0.001 versus the corresponding 
normoxic control and §§P<0.01 versus WT chronic hypoxia. 
 
Elevated pulmonary vascular resistance and sustained pulmonary hypertension put 
an excessive burden on the right ventricle and ultimately lead to right heart failure. 
Therefore, the effect of chronic hypoxia on right heart hypertrophy was assessed. 
The ratio of the right and left ventricle in normoxic conditions did not differ between 
wild-type and sEH
-/- mice. Exposure to chronic hypoxia induced a right heart 
hypertrophy in both, wild-type and sEH
-/- mice, as assessed by the ratio of the right 
ventricle /(left ventricle + septum). Compared to chronic hypoxic hearts from wild-type 
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mice sEH
-/-
 mice displayed a slightly but not significantly enhanced right/(left ventricle 
+ septum) ratio (Figure 27). 
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Figure 27: Effect of chronic hypoxia on right heart hypertrophy. Ratio of the right 
ventricular wall (RV) and the left ventricular wall+septum (LV + S) weight from hearts of wild-
type and sEH
-/- mice. Animals were kept under normoxic conditions (21% O2) or exposed to 
hypoxia (10% O2) for 21 days. The graph summarises data obtained in 10 independent 
experiments; **P<0.01, ***P<0.001 versus the corresponding normoxic control. 
 
In the isolated buffer-perfused mouse lung the quantification of baseline pulmonary 
artery pressures is a measurement that directly reflects pulmonary vascular 
resistance. Baseline pulmonary artery pressures did not differ between normoxic 
lungs from wild-type mice and sEH
-/- mice (Figure 28). Exposure of animals to 21 
days hypoxia significantly enhanced baseline pulmonary artery pressures in lungs 
from wild-type mice and sEH
-/- mice to the same extent (Figure 28). 
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Figure 28: Effect of chronic hypoxia on pulmonary artery pressure measured in 
artificially perfused lungs. Baseline pulmonary artery pressure was assessed in lungs from 
wild-type (WT) and sEH
-/- mice after the initial steady state period of lung perfusion. Lungs 
were perfused at a flow rate of 2 mL/min. Animals were kept under normoxic conditions (21% 
O2) or pre-exposed to hypoxia (10% O2) for 21 days. The graph summarises data obtained in 
5-8 independent experiments; **P<0.01, ***P<0.001 versus the corresponding normoxic 
control.  
 
3.10. Morphometric analysis of the pulmonary vasculature 
To analyse the role of the sEH in chronic hypoxia-induced pulmonary vascular 
remodelling a morphometric analysis of the pulmonary vasculature of lungs from wild-
type mice and sEH
-/- mice was performed. 
When dividing the pulmonary vessels into 3 categories (small: 20–70 µm diameter, 
medium: >70–150 µm diameter and: >150–1000 µm diameter) and analysing the 
degree of muscularisation (non-muscularised, partially muscularised, fully 
muscularised) within the different categories of vessel diameter, it appeared that 
under normoxic conditions the percentage of muscularised vessels was greater in 
sEH
-/- than in wild-type mice (Figure 29). In wild-type mice kept under chronic 
hypoxia, the number of non-muscularised vessels decreased while the number of 
partially and fully muscularised vessels increased (Figure 29), an effect also 
observed in sEH
-/- mice. When the degree of muscularisation of chronic hypoxic 
lungs was compared in wild-type mice and sEH
-/- mice the latter animals displayed an 
enhanced muscularisation index. The effect was most prominent in the medium 
vessel size category (Figure 29). 
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Figure 29: Effect of chronic hypoxia on pulmonary artery muscularisation in wild-type 
and sEH
-/- mice. The degree of muscularisation (non: non-muscularised; part: partially-
muscularised; full: fully-muscularised) is given for the following categories of vessel diameter: 
small: 20–70 µm diameter, medium: >70–150 µm diameter and: >150–1000 µm diameter. 
Data are given for wild-type and sEH
-/- mice either exposed to chronic hypoxia (21 days, 10% 
O2; hypoxia) or kept under normoxic conditions (normoxia). The graph summarises data 
obtained in 6 animals for each group. *P<0.05, **P<0.01 indicate significant differences.  
 
3.11. Chronic hypoxia and soluble epoxide hydrolase 
expression/activity  
Chronic hypoxia alters gene expression via the activation of different transcription 
factors.
173 Recently, our group reported that a CYP epoxygenase is implicated in 
chronic hypoxia-induced pulmonary hypertension and pulmonary vascular 
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remodelling.
24 The results of the present investigation indicate a role of the sEH on 
acute HPV and a vasoconstrictor role of EETs in the pulmonary vasculature. 
Therefore, the influence of hypoxia on the expression of the sEH and acute HPV was 
assessed. 
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Figure 30: Effect of chronic hypoxia on the expression and activity of the sEH. (A) 
Immunohistochemical analysis showing the expression of the sEH (in brown) in lungs from 
wild-type mice kept under normoxic conditions or after exposure to 21 days hypoxia (10% 
O2). (B) RT-PCR analysis of normoxic lungs from wild-type mice and of lungs from wild-type 
mice exposed to hypoxia (10% O2) for 1 day and 21 days. (C) Effect of chronic hypoxia on 
the generation of 14,15-DHET from 14,15-EET by lung homogenates. Wild-type mice were 
kept under normoxic conditions (Normoxia) or exposed to 21 days hypoxia (10% O2). The 
bar graph summarises data obtained in 4-16 independent experiments; *P<0.05 versus 
normoxia. 
 
As mentioned above the sEH is expressed in pulmonary vascular smooth muscle 
cells. Using immunohistochemistry it could be demonstrated that chronic exposure to 
hypoxia (10% O2) for 21 days decreased the expression of the sEH in lungs from 
wild-type mice (Figure 30A). Moreover, in lungs from wild-type mice short term (1 
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day) hypoxia decreased the sEH expression and exposure to 21 days hypoxia further 
decreased sEH levels (detected using RT-PCR, Figure 30B). Homogenates prepared 
from normoxic lungs hydrolysed 14,15-EET to 14,15-DHET, as determined by 
LC-MS/MS. The latter reaction was attenuated in lung homogenates prepared from 
animals exposed to chronic hypoxia (Figure 30C). 
 
3.12. Effect of hypoxia on sEH promoter activity 
To determine whether or not hypoxia could directly affect the expression of the sEH, 
we assessed the effect of hypoxia (1% O2) on the activity of the sEH promoter using 
a luciferase gene-based reporter assay. As reported previously,
174 significant 
luciferase activity was detected in HEK 293 cells transfected with the 4 kb sEH 
promoter. Hypoxia rapidly (within 4 hours) decreased promoter activity, an effect that 
was maintained after 24 hours (Figure 31). Similar results were obtained using a 1.5 
kb promoter fragment (Figure 31).  
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Figure 31: Effect of hypoxia (1% O2) on sEH promotor activity. HEK 293 cells were 
transfected with the 4 kb sEH promoter or the 1.5 kb sEH promoter. Promoter activity was 
assessed using a luciferase gene based reporter assay.  The graph summarises data 
obtained in 4 independent experiments; *P<0.05, **P<0.01 versus normoxia. 
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3.13. Effect of chronic hypoxia on acute hypoxic pulmonary 
vasoconstriction and pulmonary vasoreactivity 
After chronic exposure to hypoxia, an increased, decreased or unchanged acute 
HPV response has been observed depending on species, subspecies and age.
31,175-
180 However, in the mouse lung chronic exposure to hypoxia is reported to enhance 
acute HPV.
158 Given the results of the present study, modulation of the HPV 
response due to the activity of the sEH, down regulation of the sEH after exposure to 
chronic hypoxia and enhanced pulmonary artery muscularisation in sEH
-/-, the effects 
of chronic hypoxia on the acute HPV response were assessed in lungs from wild-type 
and sEH
-/- mice. 
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Figure 32: Comparison of the effects of normoxia and chronic hypoxia on pulmonary 
vascular responsiveness. Mice were kept under normoxic (21% O2) conditions or exposed 
to hypoxia (10% O2) for 21 days. (A) Acute hypoxic pulmonary vasoconstriction response to 
1% O2 (10 minutes) in lungs from wild-type (WT) and sEH
-/- mice. (B) Maximum increase in 
pulmonary artery pressures following the application of U46619 (100 nmol/L) to the 
pulmonary perfusate. The bar graphs summarise data obtained in 5-8 independent 
experiments; *P<0.05 versus normoxic WT. 
 
As before, challenging lungs with acute hypoxic ventilation for 10 min (1% O2) 
resulted in an acute increase in pulmonary artery pressure (Figure 32A), pre-
exposure to hypoxia (21 days) potentiated the acute HPV response (Figure 32A). 
Lungs from sEH
-/- mice displayed an enhanced acute HPV, compared to that 
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observed in chronic hypoxic lungs from wild-type mice. However, chronic exposure to 
hypoxia did not further potentiate the responses (Figure 32A). Indicating, that the 
chronic hypoxia-induced amplification of the acute HPV in wild-type lungs is linked to 
sEH expression. 
In lungs from normoxic wild-type mice, the application of the thromboxane mimetic 
U46619 elicited a potent vasoconstriction (Figure 32B). Pre-exposure of wild-type 
mice to chronic hypoxia for 21 days enhanced the U46619-induced vasoconstriction 
(Figure 32B). Normoxic lungs from sEH
-/- displayed an U46619-induced contraction 
that was similar compared to response observed in normoxic lungs from wild-type 
mice (Figure 32B). Chronic exposure of sEH
-/- mice to hypoxia also potentiated the 
U46619 response (Figure 32B), indicating, that the events initiated by chronic 
exposure to hypoxia did not alter the vasoreactivity to all pulmonary vasoconstrictors.  
 
3.14. Effect of chronic hypoxia on the ACU-dependent increase in 
acute hypoxic pulmonary vasoconstriction 
Given the sEH inhibition- and chronic hypoxia-induced potentiation of acute HPV 
response in wild-type mice, the absence of the latter effect in lungs from sEH
-/- mice, 
the non-responsiveness of ACU in lungs from normoxic sEH
-/- mice and the decrease 
of pulmonary sEH expression after chronic hypoxia, we assessed the effects of 
chronic hypoxia on the ACU-dependent increase in acute HPV. 
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Figure 33: Effect of sEH inhibition and EET antagonism on acute hypoxia-induced 
vasoconstriction in isolated perfused mouse lungs. Wild-type mice were kept (A) under 
normoxic conditions or exposed to (B) hypoxia (10% O2) for 21 days. Hypoxic pulmonary 
vasoconstriction was assessed in the presence or absence of 14,15-EEZE (EEZE, 10 
µmol/L), and ACU (3 µmol/L). The bar graphs summarise data obtained in 5-8 independent 
experiments; *P<0.05 versus CTL and §P<0.05, §§P<0.01 versus ACU. 
 
In normoxic lungs from wild-type mice inhibition of the sEH enhanced the acute HPV 
(Figure 33A). The EET antagonist, 14,15-EEZE, had only a marginal effect on its own 
but it completely prevented the increased constriction induced by sEH inhibition 
(Figure 33A). These data confirmed observations already presented in Figure 13. As 
before, chronic hypoxic lungs from wild-type mice displayed an enhanced acute HPV 
(Figure 32). However, sEH inhibition had no effect on acute HPV in lungs from 
chronic hypoxic wild-type mice (Figure 33B) whereas the EET-antagonist 14,15-
EEZE significantly decreased the enhanced responses in the presence of solvent 
and after ACU treatment (Figure 33B). 
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Figure 34: Effect of sEH inhibition, EET antagonism on acute hypoxic pulmonary 
vasoconstriction in isolated buffer-perfused mouse lungs. sEH
-/- mice were kept under 
(A) normoxic conditions or exposed to (B) hypoxia (10% O2) for 21 days. Hypoxic pulmonary 
vasoconstriction was assessed in lungs from sEH
-/- mice in the presence or absence of 
14,15-EEZE (EEZE, 10 µmol/L), or ACU (3 µmol/L). The bar graphs summarise data 
obtained in 4-7 independent experiments; *P<0.05 versus CTL and §P<0.05, §§P<0.01 
versus ACU. 
 
As expected, in normoxic and chronic hypoxic lungs from sEH
-/- mice ACU did not 
further potentiate the acute HPV (Figure 34A&B). However, responses returned to 
levels observed in normoxic lungs from wild-type animals in the presence of 14,15-
EEZE (Figure 34). Indicating that the chronic hypoxia-induced downregulation of the 
sEH is implicated in the increased HPV response in chronic hypoxic lungs from wild-
type and that the mediator involved might be one of the EET isomers. 
 
3.15. sEH expression and pulmonary hypertension  
Pulmonary hypertension is a disabling disease with high mortality characterised by 
sustained elevation in pulmonary artery pressure and pulmonary vascular 
remodelling due to proliferation and migration of pulmonary artery smooth muscle 
cells.
181 Imbalance of vasodilatory and vasoconstrictive mediators have been 
implicated in these changes and immunohistological studies showed reduced 
expression of PGI2 synthase in pulmonary vessels from patients with pulmonary 
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hypertension.
182 However, little is known about the expression of the sEH in patients 
with pulmonary hypertension. Immunohistochemistry demonstrated an extensive 
expression of the sEH in the medial wall of pulmonary arteries in lungs from healthy 
donors (Figure 35). sEH expression was, however, diminished in samples from 
ulmonary hypertension patients (Figure 35) 
n) in samples from human donors or pulmonary 
ypertension (PH) patients.  
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Figure 35: sEH expression and pulmonary hypertension. Immunohistochemical analysis 
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4. Discussion 
4.1.  The role of the sEH and EETs in acute hypoxic pulmonary 
vasoconstriction 
The results of the present investigation indicate that the activity/expression of the 
sEH plays an important role in determining the magnitude of acute hypoxia-induced 
pulmonary vasoconstriction. The mechanism involved appears to be related to the 
generation of CYP epoxygenase-derived epoxides because both the epoxygenase 
inhibitor and the EET antagonist abrogated the effects of sEH inhibition and the 
exogenous application of 11,12-EET elicited a rapid increase in pulmonary perfusion 
pressure. Both hypoxia and 11,12-EET were able to elicit the activation of the 5-HT2A 
receptor, as responses were sensitive to 5-HT2A antagonists, as well as the Rho 
kinase. Moreover, both hypoxia and 11,12-EET stimulated the translocation of 
TRPC6 channels within pulmonary smooth muscle cells indicating that the EET-
induced activation of TRPC6 underlies the phenomenon observed. As EET-induced 
translocation of TRPC6 channels was sensitive to 5-HT2A receptor but not to Rho 
kinase inhibition, activation of the latter either occurs downstream or independently of 
the TRPC6 channel. 
In the systemic circulation one function of CYP epoxygenase-derived EETs is to elicit 
the hyperpolarisation of endothelial and vascular smooth muscle cells and thus 
vasodilation. CYP-dependent vasoconstriction, on the other hand, is generally 
attributed to metabolites such as 20-HETE,
183 which play an important role in the 
myogenic tone. The biological role of CYP-derived metabolites in the pulmonary 
circulation remains unclear and completely contradictory findings have been 
published. Although classed as vasodilators in the systemic circulation EETs have 
previously been linked with constriction in the pulmonary circulation.
84,89,90 However, 
vasodilatation seems to be restricted to larger conduit arteries as smaller resistance 
arteries contract in response to the exogenous application of EETs.
184 Thus, in order 
to analyse the role of EETs in the pulmonary circulation, the isolated buffer-perfused 
mouse lung seems a more suitable model than isolated arterial rings to study global 
effects of the arachidonic epoxides on resistance in the pulmonary microcirculation. 
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Biological activity has been attributed to all of the EET regioisomers generated in the 
lung. However, our study highlights the importance of 11,12-EET as exposure to 
hypoxia acutely increased the production of 11,12-EET in murine lung microsomes 
and in intact rat pulmonary artery smooth muscle cells; a response also recently 
observed in the rabbit lung.
185 Moreover, two CYP epoxygenase inhibitors, MSPPOH 
and fenbendazole, attenuated the generation of 11,12- and 14,15-EET without 
affecting that of either 5,6- or 8,9-EET and abrogated the effects of sEH inhibition on 
hypoxic vasoconstriction. For these reasons, the direct effects of 11,12- and 14,15-
EET on pulmonary artery pressure in the isolated mouse lung were assessed. 
Exogenously applied 11,12-EET elicited a pronounced concentration-dependent 
increase in pulmonary perfusion pressure while 14,15-EET was surprisingly without 
effect. Generation of the corresponding diol is also unlikely to account for the 
observations made as 11,12-DHET had no effect on pulmonary artery pressure. Our 
observation that 11,12-EET is a potent vasoconstrictor within the pulmonary 
vasculature is at odds with reports that EETs cause vasodilation in the pulmonary 
circulation.
83,86,87 Such contradictory observations suggest that the pulmonary effects 
of EETs are not straightforward and appear to depend on factors such as species, 
concentration, size of the vessel (as mentioned above), model, and EET isomer. 
Indeed, all of the studies demonstrating EET-dependent pulmonary vasodilation were 
focused on 5,6-EET. In the present investigation only 11,12-EET and not 14,15-EET 
increased pulmonary artery pressure whereas other investigators found that 11,12- 
and 14,15-EET increased pulmonary resistance and constricted isolated pulmonary 
artery rings to the same magnitude.
84,89 
As we reasoned that more information about the biological actions of pulmonary-
derived EETs can be obtained from experiments in which their metabolism was 
prevented than from experiments looking at responses to exogenously applied 
eicosanoids, our investigation focused on the importance of the sEH in modulating 
the acute hypoxic pulmonary vasoconstriction. Our results clearly show that inhibition 
of the sEH potentiated acute hypoxic vasoconstriction in lungs from wild-type mice 
and that this potentiating effect was not observed when CYP epoxygenases were 
inhibited. The two compounds used, ACU and AEPU, are both potent sEH inhibitors 
with IC50 values in the low nmol/L range for both the human and the murine 
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recombinant enzymes. However, their structures and physical properties are quite 
different
24 and the fact that these divergent compounds led to very similar pulmonary 
responses supports the conclusion that their action was due to the inhibition of the 
sEH. In keeping with these observations the acute increase in pulmonary perfusion 
pressure induced by hypoxia was markedly elevated in lungs from sEH
-/- mice 
underlining the importance of the sEH and CYP epoxygenase-derived EETs in the 
acute hypoxic pulmonary vasoconstriction response. In sEH
-/- mice, which 
demonstrate elevated circulating and pulmonary levels of EETs and low DHET 
levels,
186 neither of the sEH inhibitors tested were able to affect the acute pulmonary 
vasoconstriction induced by hypoxia, whereas a CYP epoxygenase inhibitor and the 
EET antagonist decreased the acute HPV response in lungs from sEH
-/- mice up to 
levels observed in lungs from wild-type mice. Thus, the sEH inhibitor-induced 
increase in pulmonary vasoconstriction that was dependent on the activity of a CYP 
epoxygenase, seems to be attributable to 11,12-EET. Furthermore, an indirect effect 
of 11,12-EET on interstitial/alveolar oedema, which could elicit a “secondary” hypoxic 
vasoconstriction, could be ruled out, as we found no evidence to suggest that 11,12-
EET affected endothelial cell permeability. 
The involvement of CYP enzymes in the regulation of acute hypoxic pulmonary 
vasoconstriction has been proposed previously on the basis of earlier investigations 
reporting that CYP inhibition decreased acute hypoxic pulmonary vasoconstriction in 
the isolated rabbit lung,
187 and depressed venular contractions induced by decreased 
pO2.
188 Recently a collaborative study between our group and others implicated a 
CYP epoxygenase in the acute pulmonary vasoconstriction induced by hypoxia in 
anaesthetised mice.
24 In the latter study it was also possible to demonstrate that the 
mediator involved was metabolised by the sEH, as inhibition of this enzyme 
potentiated the vasoconstrictor response.
24 One apparent difference between the 
present investigation in the isolated lung and the previous study in anaesthetised 
animals was the sensitivity of the hypoxic vasoconstriction per se to CYP 
epoxygenase inhibition.
24 This difference can most likely be attributed to the methods 
used to assess pulmonary function as pressures measured in the isolated lung model 
are generally lower than those measured in vivo. Further support for a prominent role 
of an arachidonic acid product in the pulmonary vasoconstrictor response to hypoxia 
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has been obtained using animals lacking the cytosolic phospholipase (cPL) A2 that 
releases arachidonic acid from phospholipids in cell membranes.
189 In the latter 
study, hypoxic pulmonary vasoconstriction induced by left main stem bronchus 
occlusion was detectable in wild-type but not in cPLA2
-/- mice and could be restored 
in these animals by the exogenous application of arachidonic acid. Moreover, 
inhibition of the cPLA2 in wild-type animals resulted in a complete loss in hypoxic 
pulmonary vasoconstriction. However, all of the studies that have addressed a 
possible role of CYP in acute hypoxic pulmonary vasoconstriction observed that CYP 
inhibition resulted in decreased and not in a total loss of acute hypoxic 
vasoconstriction. As deletion of the cPLA2 resulted in a complete loss in HPV, it 
seems that other arachidonic acid metabolising enzymes and arachidonic acid-
derived-products are involved in regulating pulmonary vascular tone.  
One point that this study did not address in detail relates to the cellular localisation of 
the enzymatic machinery involved. Although, still to be confirmed experimentally by 
immunohistochemistry and in-situ hybridisation, we propose that the CYP2C 
enzymes and the sEH that mediate HPV are localised in vascular smooth muscle 
cells. Certainly these cells express the sEH in vivo in mice and the cultured rat 
pulmonary artery smooth muscle cells we used to demonstrate hypoxia induced 
translocation of TRPC6 expressed both CYP2C11 and the sEH. Evidence against an 
endothelial location of the hypoxia-sensitive CYP enzyme was obtained in 
experiments looking at responses in transgenic mice which overexpressed either 
CYP2C8 or 2J2 specifically in endothelial cells. In the latter animals we failed to 
observe an enhanced hypoxic pulmonary vasoconstriction even in the presence of 
ACU. Our supposition that the CYP and sEH enzymes are extra-endothelial fits with 
reports in the literature that pulmonary smooth muscle cells contain the primary 
oxygen sensor and mediators.
5,11 
sEH activity is increased in male mice versus female mice and castration is reported 
to decrease sEH activity and expression; a phenomenon restored by testosterone 
supplementation.
99,100 Thus, one would assume that female or castrated male mice 
display higher EET levels compared to normal male mice resulting in an exaggerated 
hypoxic pulmonary vasoconstriction and sensitivity to sEH inhibition. Although we 
previously observed greater sensitivity to sEH inhibition in female Swiss Webster 
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mice
24 this finding could not be reproduced in C57BL/6 mice and there were no 
differences in hypoxia-induced pulmonary vasoconstriction in male, male castrated, 
female or female ovarectomised animals. However, we did not make a detailed 
comparison of sEH expression in the different groups to determine whether the 
differential sEH expression reported in the ventral prostate, liver and kidneys were 
also apparent in the lung. Certainly, there are examples of sexual hormone regulated 
enzymes (e.g. the murine cytosolic glutathione S-transferase
190) that are modified in 
the heart, liver and kidneys but not in the pulmonary system. 
Contraction of smooth muscle cells occurs via Ca
2+-dependent mechanisms requiring 
an increase in intracellular Ca
2+ as well as via Ca
2+-independent mechanisms related 
to the activation of the Rho kinase.
191-194 Hypoxic vasoconstriction has been linked to 
Rho kinase activation in a number of studies
162,163,195 as has the 20-HETE-induced 
contraction of coronary arteries.
70 Given that the actions of 11,12-EET and 20-HETE 
seem to be reversed in the lung,
196,197 we determined whether or not hypoxia, sEH 
inhibition and/or 11,12-EET were able to affect the activity of the Rho kinase. Our 
results demonstrate that sEH inhibition increases the hypoxia-induced 
phosphorylation of MLC-20 and that 11,12-EET is able to stimulate Rho kinase 
activity in the murine lung. Moreover, Rho kinase inhibition decreased the basal 
acute hypoxic pulmonary vasoconstriction an effect that was also observed by other 
investigators.
162,163 Furthermore, Rho kinase inhibition prevented not only the sEH 
inhibitor-induced potentiation of hypoxic vasoconstriction but also the increase in 
pulmonary artery pressure elicited by exogenous 11,12-EET. 
Rho kinase activation is linked to G protein-coupled receptors, mainly via Gα12/13-
coupled receptors.
198 However, activation of the Rho kinase can also occur via a 
Gαq-coupled mechanism
199 and seems to be dependent on the activation of PKC.
200-
202 As 5-HT is one of the best studied modulators of the HPV response
11,164 and the 
5-HT2A receptor, a Gαq-coupled receptor, is mainly expressed on pulmonary artery 
smooth muscle cells,
145 we determined whether or not hypoxia and/or 11,12-EET can 
activate the 5-HT2A receptor. Our results showed that inhibition of the 5-HT2A receptor 
decreased the basal acute hypoxic vasoconstriction by approximately 30% and 
completely prevented the EET induced potentiation of the HPV response. Moreover 
the sEH inhibitor-induced potentiation of HPV was sensitive to two different 5-HT2A 
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receptor inhibitors. Both of the compounds used, ketanserin and ritanserin, are 
potent inhibitors of the 5-HT2A receptor and the concentration used in the present 
investigation were close to the IC50 values (approximately 1nmol/L). Ketanserin is a 
relatively selective 5-HT2A receptor antagonist. It also binds less potently to 5-HT2C, 
5-HT2B, 5-HT1D, alpha-adrenergic, and dopamine receptors.
203 Ritanserin is more 
selective for the 5-HT2A receptor but also binds in higher concentrations to the 5-HT2C 
receptor.
204 However, the fact that both substances lead to similar responses on the 
sEH inhibitor-induced potentiation of acute hypoxic vasoconstriction and that 
ritanserin in low doses inhibited the 11,12-EET-induced actions indicate that hypoxia, 
sEH inhibition, and 11,12-EET signal via the 5-HT2A receptor. 
There are numerous agonists (e.g. bradykinin, angiotensin II) known to activate G 
protein-coupled receptors that also increase endogenous CYP activity and EET 
production but none seem to be as exquisitely sensitive to EET modulation as the 5-
HT2A receptor. Furthermore, given that the effects described were sensitive to the 
EET antagonist 14,15-EEZE we speculate a much closer link between EETs and the 
5-HT2A receptor than previously proposed. In fact, as the 5-HT2A receptor antagonist 
was able to prevent the 11,12-EET-induced translocation of TRPC6 in pulmonary 
smooth muscle cells it may be possible that 11,12-EET can activate the 5-HT2A 
receptor directly. Although a specific “EET receptor” on the cell surface remains to be 
identified its existence has been suggested on the basis of data showing a specific 
EET binding site on mononuclear cells.
205-207 The authors of the latter studies 
proposed that EET-signalling begins with the binding of the EET to its receptor and is 
followed by an increase in intracellular cAMP levels and the activation of PKA.
205-207 
The cAMP/PKA pathway is also involved in the 11,12-EET-induced translocation of 
the TRPC6 in endothelial cells,
69 indicating that in monocytes and endothelial cells a 
Gαs- coupled receptor is likely to act as a potential EET receptor. In the present study 
the 11,12-EET- and/or sEH inhibition-induced responses in pulmonary artery 
pressure were sensitive to 14,15-EEZE. The later is a so called “EET antagonist” a 
fact that makes the possibility that 11,12-EET signals via a receptor more likely. A 
more detailed investigation of the link between 11,12-EET and the 5-HT2A receptor is 
ongoing. 
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Although the Rho kinase can be activated in the absence of a sustained increase in 
intracellular Ca
2+,
208,209 there is a wealth of evidence indicating that Ca
2+ plays a 
pivotal role in pulmonary vasoconstriction. While the activation of several types of 
Ca
2+ channels can affect [Ca
2+]i in smooth muscle cells, a lot of attention has been 
focused on the role played by the TRP family of non-selective cation channels. To 
identify the potential mechanism of the hypoxia-induced, EET-mediated pulmonary 
vasoconstriction we concentrated on the TRPC6 channel. EETs can affect the 
activity of at least 2 different classes of TRP channels (i.e. TRPV and TRPC 
channels) but there were several reasons for singling out TRPC6 as an effector for 
11,12-EET. Firstly, although CYP epoxygenases can modulate the activity of TRPV4, 
a channel implicated in mechanotransduction, these effects have been attributed to 
5,6- and 8,9-EET but not 11,12-EET.
68 Secondly, while TRPC6 is unaffected by 
shear stress, hypo-osmotic stress and by 5,6-EET, both its membrane translocation 
and Ca
2+ influx are influenced by 11,12-EET.
69 It is likely that the spectrum of EET 
regioisomers generated in response to a given stimulus determines which TRP 
channels can be affected. Indeed, TRPC6 can also be activated by CYP-derived 20-
HETE in HEK cells overexpressing the channel.
210 Moreover, although relatively few 
studies have addressed the role of hypoxia in the regulation of TRP channels, the 
expression of TRPC6 and store- as well as receptor-operated Ca
2+ entry into 
pulmonary artery smooth muscle cells are elevated in response to chronic (3 weeks) 
hypoxia,
14 and acute hypoxic vasoconstriction is almost abolished in the lungs of 
TRPC6
-/- mice.
115 The results generated during the preparation of this thesis 
demonstrated that neither hypoxia nor 11,12-EET were able to stimulate an increase 
in pulmonary perfusion pressure in lungs from TRPC6
-/- mice. The lack of 
responsiveness to hypoxia and 11,12-EET appears to be a specific phenomenon as 
the responsiveness of the lungs from TRPC6
-/- mice to U46619 was normal
115 and 
aortic rings from these animals even demonstrate an elevated contractile response to 
phenylephrine.
152 Given that 11,12-EET has been demonstrated to increase Ca
2+ 
entry and elicit the translocation of the TRPC6 channel from the peri-nuclear Golgi 
apparatus to caveolae,
69 we determined whether or not hypoxia could induce the 
translocation of the TRPC6 channel in pulmonary smooth muscle cells and whether 
or not this was an EET-dependent process. Indeed, hypoxia stimulated the 
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membrane translocation of a TRPC6-V5 fusion protein to membrane domains 
enriched with caveolin-1, an effect that was mimicked by 11,12-EET and markedly 
attenuated in the presence of the EET antagonist. Moreover, the 11,12-EET-induced 
TRPC6-V5 translocation was diminished upon 5-HT2A receptor inhibition and 
unaffected by the Rho kinase inhibitor. Although our data suggest that the hypoxia 
and/or 11,12-EET-induced TRPC6 channel translocation depends on the activation 
of the 5-HT2A receptor, the intermediate steps in the translocation process e.g. 
eventual involvement of PKA, remains to be determined. However, it seems safe to 
conclude that the EET-induced activation of RhoA/Rho kinase either occurs 
downstream of the TRPC6 channel or independently of the TRPC6 channel-induced 
increase in [Ca
2+]i.  
The exact mechanism by which translocation of TRP channels occurs remains 
unclear. For the TRPC1, TRPC3, TRPC4, TRPC6 and TRPV6 channels caveolae 
have been implicated
69,211-214 and for TRPC1 the activation of a G protein coupled 
receptor is assumed.
132 In endothelial cells, the EET-induced translocation of TRPC6 
to caveolae was dependent on a signalling cascade including cAMP/PKA.
69 In rat 
pulmonary artery smooth muscle cells, the 5-HT2A receptor coimmunoprecipitates 
with caveolin-1 and the KV1.5 channel which is another potential hypoxia target.
215 
Moreover, KV1.5 channels were internalised when cells were stimulated with 5-HT,
215 
thus it will be interesting to determine whether EETs stimulate the association of 5-
HT2A with TRPC6 or interfere with the activation/inactivation of this complex. 
G protein-coupled receptors are involved in multiple ways in the activation or 
translocation of TRP channels. Recently, thrombin was reported to bind to and 
cleave protease-activated receptor-1 in human endothelial cells leading to the Gαq 
receptor-dependent activation of the TRPC6 channel.
202 Further, the TRPC6-induced 
rise in [Ca
2+]i activated PKCα thus causing the activation of the Rho kinase.
202 
However, in the latter study it was not determined whether thrombin induced the 
translocation of TRPC6 to the plasma membrane and the authors linked the 
activation of the TRPC6 channel to increased levels of DAG.
202 It is however possible 
that a similar pathway could link the activation of the 5-HT2A receptor to TRPC6-
dependent Ca
2+ influx. There are also hints in the literature that the activation of small 
G proteins occurs upstream of TRP channel translocation. For example, the thrombin 
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induced translocation of TRPC1 channels in endothelial cells requires active 
RhoA,
132 the translocation of TRPC5 channels in hippocampal neurons is dependent 
on the activation of the Rho GTPase Rac1
136 and the trafficking of TRPV5 and V6 
channels to the plasma membrane in epithelial cells depends on the activation of 
Rab11.
216 Other factors that are discussed to be involved in the translocation of the 
TRP channel are proteins like VAMP2, Homers, RGA and PASCIN3.
217 
Taken together, our results indicate that the activity of the sEH is an important 
determinant of the magnitude of hypoxic pulmonary vasoconstriction by inactivating 
vasoconstrictor CYP-derived EETs. These eicosanoids appear to be important 
modulators of pulmonary vascular tone and can elicit contraction by targeting TRPC6 
channels to the plasma membrane as well as by activating the Rho kinase. The exact 
molecular mechanism(s) by which EETs induce the membrane translocation of 
TRPC6 channels and the activation of the Rho kinase also remains to be elucidated 
but seems to involve the activation of the 5-HT2A receptor.  
 
4.2.  The sEH in chronic hypoxia-induced pulmonary hypertension 
and pulmonary vascular remodelling 
From the initial part of this study it seems clear that the expression of the sEH plays 
an important role in modulating responsiveness to acute hypoxia. The second part of 
this study was therefore aimed at investigating a potential link between chronic 
hypoxic alterations in lung responsiveness and morphology and the 
expression/activity of the sEH. Our results indicate that deletion of the sEH mimics, to 
a certain extent, the pathophysiological changes induced in the lung by chronic 
(21 days)  hypoxia.  Certainly, even under normoxic conditions the muscularisation 
index of the sEH
-/- mice differed from that of wild-type mice and the acute hypoxia-
induced pulmonary vasoconstriction was significantly elevated. Moreover, in wild-
type animals, chronic hypoxia decreases pulmonary sensitivity to sEH inhibition at 
the same time as decreasing sEH mRNA and protein expression as well as activity. 
While it was not possible to demonstrate a causative link between sEH expression 
levels and the development of pulmonary hypertension, we routinely failed to detect 
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the sEH in lungs from patients with pulmonary hypertension even though the enzyme 
was expressed in vascular smooth muscle cells in lungs from healthy donors. 
Pulmonary hypertension is a disabling disease with a high mortality characterised by 
sustained elevation in pulmonary artery pressure and pulmonary vascular 
remodelling that results from the proliferation and migration of pulmonary artery 
smooth muscle cells.
181 Chronic alveolar hypoxia is a major stimulus for the 
development of pulmonary hypertension and the subsequent changes in the 
architecture of the pulmonary vasculature.
218 Among the signalling intermediates 
implicated to-date are cyclooxygenase and lipoxygenase products of arachidonic 
acid as wells as the nitric oxide pathway. Surprisingly little is known about the role, if 
any played by CYP epoxygenases in the homeostasis of the pulmonary 
circulation
218,219 even though these enzymes were recently implicated in the 
pulmonary vascular remodelling induced by prolonged (7 days) hypoxia and CYP 
epoxygenase inhibition attenuated remodelling.
24  
It is well established that hypoxia-induced pulmonary hypertension increases right 
ventricular after load thus resulting in right heart hypertrophy and failure.
220 Although 
the muscularisation ratio was affected by the loss of the sEH even in normoxic 
conditions and the pulmonary vasoconstriction elicited by acute exposure to hypoxia 
was elevated by sEH deletion and inhibition, there was no evidence of an 
accompanying right heart hypertrophy and failure in the sEH
-/- animals maintained 
under normoxic conditions. Moreover, chronic hypoxia elicited comparable changes 
in right ventricular mass in both wild-type and sEH
-/- mice, even though responses 
were slightly more pronounced in sEH
-/- animals. Similarly, baseline pulmonary artery 
pressure (measured in the isolated lung) was not significantly different in lungs from 
the two strains following exposure to hypoxia. Interestingly, there was a marked 
increase in the hematocrit of the hypoxic sEH
-/- mice versus the wild-type animals, 
suggesting that the former are particularly sensitive to hypoxia, however, a more 
detailed investigation of the link between erythropoiesis and the activity of the sEH 
needs to be performed. Certainly, given the link between excessive erythrocytosis 
and cardiovascular risk as well as the development of pulmonary hypertension
171,181 
and the fact that arachidonic acid administration also induces erythropoiesis
170 may 
implicate the cytochrome P450 pathway in this process. 
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Our finding that the muscularisation of small-sised (20-70 µm) arteries was greater in 
sEH
-/- mice even in normoxia suggests that hypertrophic mechanisms are activated in 
these animals. Certainly, EETs have the potential to promote such a response as 
these epoxides are reported to enhance cell survival
221,222 as well as to elicit the 
phosphorylation of MAP kinases, particularly p38 MAP kinase and ERK1/2, all of 
which can contribute to pulmonary smooth muscle cell hypertrophy.
223,224 In this 
context, it is interesting to note that 11,12-EET promoted capillary muscularisation 
and maturation in a Matrigel plug assay in vivo,
225 although the exact cellular 
mechanisms that underlie the increase in vascular muscular mass need to be 
determined experimentally. Whether or not TRPC6 channels are involved in these 
processes is also unclear, since although channel expression was increased in 
hypoxia-induced, as well as idiopathic chronic pulmonary hypertension,
14,127 the 
development of pulmonary hypertension did not differ in TRPC6
-/- and wild-type 
mice.
115  
The molecular pathways by which chronic hypoxia causes vasoconstriction and 
pulmonary vascular remodelling are just beginning to be identified. However, given 
that 11,12-EET, which is an sEH substrate, can elicit pulmonary vasoconstriction as 
well as vascular maturation,
225 we hypothesise that the development of pulmonary 
hypertension might be linked to a change in the CYP epoxygenase/sEH pathway. 
Certainly, hypoxia has been previously reported to increase pulmonary CYP 
epoxygenase expression and EET levels.
24,185 The latter activation would however 
not be expected to elicit a biological effect should the activity of the sEH be increased 
in parallel. The results of the present investigation indicate that hypoxia effectively 
decreased the expression of the sEH in vivo in animals exposed to hypoxia for as 
short as one day and decreased the activity of the sEH promoter in cells cultured 
under hypoxic conditions for only a few hours. It has been possible to link the sEH 
with pathology as enzyme expression is increased in spontaneously hypertensive 
and stroke-prone rats as well as in Wistar rats following the administration of 
angiotensin II.
226 However, little is known about the mechanisms regulating the 
expression of the sEH although both the binding of SP-1
174 and c-Jun
226 to the sEH 
promoter have been reported to regulate activity. Irrespective of the mechanisms 
involved, the decrease in EET metabolism resulting from the hypoxia-induced 
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downregulation of the sEH would be expected to enhance pulmonary EET levels, 
thus causing pulmonary vasoconstriction. There are however alternative, less 
efficient ways of controlling cellular EET levels; for example β-oxidation or C2 
elongation
59,227 that may limit the pathology observed.  
Nothing is known about the expression of CYP epoxygenases or the sEH in 
pulmonary hypertension patients. We observed that sEH expression was low to 
absent in samples from pulmonary hypertension patients whereas an extensive sEH 
expression was detected in the medial wall from donor lungs. The loss of a 
vasoconstrictor metabolising enzyme in human pulmonary hypertension is consistent 
with the findings in the animal experiments and fits in the hypothesis that the sEH 
and EETs are implicated in the development of pulmonary hypertension and 
pulmonary vascular remodelling. 
Hypoxic pulmonary vasoconstriction consists of two phases: the first is the so-called 
acute hypoxic vasoconstriction that generally develops within minutes of exposure 
and is followed by a temporary vasodilatation. The second phase is sustained and 
can develop twenty to thirty minutes after challenge and last for hours or days if 
hypoxia is maintained.
6 Following chronic exposure to hypoxia, an increased, 
decreased or unchanged acute hypoxic pulmonary vasoconstriction has been 
observed depending on species, subspecies and age.
228 In the mouse lung chronic 
exposure to hypoxia has been reported to enhance the acute response,
158 a finding 
confirmed by this study. Moreover, we observed that the pulmonary vasoconstriction 
elicited by acute exposure to hypoxia in lungs from wild-type mice exposed to 
hypoxia for 21 days was largely abolished in the presence of 14,15-EEZE, implicating 
an EET in the response. Chronic exposure of sEH
-/- mice to hypoxia however did not 
potentiate the acute hypoxic pulmonary vasoconstrictor response. We interpret this 
finding in the light of the chronic hypoxia-induced decrease in sEH expression as 
providing evidence of a functional consequence for a change in sEH activity in the 
pulmonary vasculature.  
At this stage it is important to note that, although we have concentrated on 11,12-
EET as the sEH substrate with the potential to alter pulmonary function and 
morphology, the enzyme can hydrolyse a number of substrates including 
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leukotrienes and EpoMEs to their corresponding diols. Our reasons for focusing on 
11,12-EET were related to our findings regarding the effects of hypoxia on CYP 
expression and the fact that that the acute hypoxic vasoconstriction was significantly 
attenuated by the EET antagonist 14,15-EEZE. However, it is certainly possible that 
one of the non-EET substrates of the sEH might be implicated in the pulmonary 
changes recorded in sEH
-/- mice. Certainly, EpoMEs have been reported to cause 
pulmonary contraction and induce lung injury
229,230 and thus might be implicated in 
the observed pathology. Leukotrienes, on the other hand, do not participate in 
hypoxic pulmonary vasoconstriction, and are reported to exert anti-proliferative rather 
than pro-proliferative actions.
231-233 Furthermore, the leukotriene diol is an important 
mediator of the adult respiratory distress syndrome, and sEH inhibition in this 
situation has been clearly linked with beneficial effects.
234,235 
In summary, the results of the present investigation support a role for the sEH and 
CYP derived EETs in the development of pulmonary hypertension and pulmonary 
vascular remodelling. It was possible to demonstrate that hypoxia decreases the 
expression of the sEH and that deletion of the sEH enhances chronic hypoxia-
induced vascular remodelling. Moreover, we were unable to detect the sEH in 
samples from lungs obtained from patients with pulmonary hypertension. An aspect 
that is important to highlight is that, based on experimental data showing that sEH 
inhibitors attenuate hypertension in spontaneously hypertensive rats
101 and in 
angiotensin II-treated mice,
104 sEH inhibitors are currently being developed for the 
treatment of human hypertension and inflammation/atherosclerosis. Given the 
apparent involvement of CYP epoxygenases in pulmonary remodelling, in particular 
in response to hypoxia,
24 these compounds may even promote the development of 
pulmonary hypertension. 
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5. Summary 
Hypoxic pulmonary vasoconstriction (HPV) redistributes pulmonary blood flow from 
areas of low oxygen partial pressure to areas of normal or relativity high oxygen 
availability, thus optimising the matching of perfusion to ventilation and preventing 
arterial hypoxemia. Generalised alveolar hypoxia results in a sustained increase in 
pulmonary artery pressure which in turn leads to structural changes in the walls of 
the pulmonary vasculature (pulmonary vascular remodelling). Recent findings have 
indicated a role for cytochrome P450 (CYP) epoxygenase-derived 
epoxyeicosatrienoic acids (EETs) in hypoxia-induced pulmonary vasoconstriction. 
Given that the intracellular concentration of EETs is determined by the soluble 
epoxide hydrolase (sEH), which metabolises EETs to their less active 
dihydroxyeicosatrienoic acids (DHETs), we assessed the influence of the sEH and 
EETs on pulmonary artery pressure, acute and chronic HPV, and pulmonary vascular 
remodelling in the mouse lung. 
In isolated lungs from wild-type mice, acute HPV was significantly increased by sEH 
inhibition, an effect abolished by pre-treatment with CYP epoxygenase inhibitors and 
the EET antagonist 14,15-EEZE. The acute hypoxia-induced vasoconstriction and 
EET production were greater in lungs from sEH
-/- mice than from wild-type mice and 
sEH inhibition had no further effect on HPV in lungs from the former animals, while 
MSPPOH (CYP epoxygenase inhibitor) and 14,15-EEZE decreased the response. 
Exogenous application of 11,12-EET increased pulmonary artery pressure in a 
concentration-dependent manner and enhanced acute HPV in wild-type lungs, while 
14,15-EET and 11,12-DHET were without significant effect on pulmonary artery 
pressure. 5-HT2A receptor antagonism or Rho kinase inhibition shifted the EET 
concentration-response curve to the right and abrogated the EET- and sEH 
inhibition-induced potentiation of acute hypoxic vasoconstriction. In lungs from wild-
type and sEH
-/-  mice, hypoxic preconditioning (hypoxic ventilation for 10 minutes) 
enhanced the 5-HT response. 1-Adamantyl-3-cyclohexylurea (ACU), a sEH inhibitor, 
further amplified the hypoxia-induced 5-HT-hypersensitivity in wild-type mice. 
However, after hypoxic preconditioning, the sEH
-/- lungs displayed a striking leftward 
shift in the 5-HT response. 11,12-EET can activate TRPC6 channels in endothelial 
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cells by eliciting its translocation to the plasma membrane, more specifically to 
membrane domains enriched with the caveolae marker caveolin-1. This effect was 
also observed in rat pulmonary artery smooth muscle cells overexpressing the 
channel. Exposure of the latter cells to acute hypoxia also stimulated the intracellular 
translocation of TRPC6 to caveolae, an effect that was sensitive to the EET 
antagonist. The EET-induced translocation of TRPC6 channels was prevented by a 
5-HT2A receptor antagonist but not by a Rho kinase inhibitor. Moreover, while acute 
hypoxia and 11,12-EET increased pulmonary pressure in lungs from TRPC6
+/- mice, 
lungs from TRPC6
-/- mice did not respond to either stimuli. These results indicate that 
the sEH and CYP-derived EETs are involved in acute HPV and that EET-induced 
pulmonary contraction under normoxic and hypoxic conditions involves a TRPC6 
channel, a 5-HT2A receptor-dependent pathway and Rho kinase activation. 
In the second part of the study the role of the sEH in the development of pulmonary 
hypertension and vascular remodelling induced in mice by exposure to hypoxia (10% 
O2) for 21 days was analysed. In wild-type mice, chronic hypoxia decreased the 
pulmonary expression/activity of the sEH, induced right heart hypertrophy and 
erythropoiesis, and increased the number of partially and fully muscularised 
pulmonary resistance arteries (by 3-fold). Moreover, in HEK 293 cells, hypoxia (1% 
O2  up to 24 h) decreased sEH promoter activity by 50%. In isolated lungs, pre-
exposure to chronic hypoxia significantly increased baseline perfusion pressures and 
potentiated the acute HPV. While an sEH inhibitor, ACU, potentiated acute HPV in 
lungs from mice maintained in normoxic conditions, it had no effect on HPV in lungs 
from mice exposed to hypoxia. The EET antagonist, 14,15-EEZE, abolished the sEH 
inhibitor-dependent increase in acute HPV in normoxic lungs and decreased HPV in 
chronic hypoxic lungs. Hypoxia-induced right heart hypertrophy and erythropoiesis 
were more pronounced in sEH
-/- than in wild-type mice. Under normoxic and hypoxic 
conditions the muscularisation of resistance pulmonary arteries was greater in lungs 
from sEH
-/- mice than in lungs from wild-type mice. sEH
-/- mice also displayed an 
enhanced acute HPV, compared to that observed in wild-type mice and chronic 
exposure to hypoxia did not further potentiate acute HPV. However, in the presence 
of 14,15-EEZE responses returned to levels observed in normoxic lungs from wild-
type animals. Furthermore, immunohistochemistry demonstrated an extensive 
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expression of the sEH in the medial wall of pulmonary arteries from human donor 
lungs. Whereas sEH expression was not detectable in samples from pulmonary 
hypertension patients, indicating that the sEH is involved in hypoxia-induced 
pulmonary vascular remodelling and hypoxic pulmonary vasoconstriction. 
Taken together, the results presented in this thesis indicate that the 
expression/activity of the sEH is an important determinant of the magnitude of acute 
and chronic hypoxia-induced pulmonary vasoconstriction and pulmonary vascular 
remodelling by inactivating vasoconstrictor CYP-derived EETs. As sEH inhibitors are 
currently being developed for the treatment of human systemic hypertension, it 
should be noted that these compounds may even promote the development of 
pulmonary hypertension. 
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6. Zusammenfassung 
Die akute hypoxische pulmonale Vasokonstriktion (HPV) ist ein physiologischer 
Mechanismus, der es erlaubt, den lokalen Blutfluss der Lunge an alveolaren O2- 
Mangel anzupassen. Durch die Hypoxie-bedingte Widerstandserhöhung besteht die 
Möglichkeit, die Durchblutung schlecht ventilierter Lungenbezirke einzuschränken 
und den Blutstrom in gut ventilierte Gebiete zu leiten. Die HPV wurde erstmals im 
Jahr 1946 durch von Euler und Liljestrand beschrieben und ist bis heute Gegenstand 
intensiver Forschung. Dennoch sind die Signaltransduktionswege und die Sauerstoff-
Sensoren, die in die HPV involviert sind, weitgehend unbekannt. Als Sensoren 
werden unter anderem die Mitochondrien und die NADPH-Oxidasen diskutiert. 
Allerdings konnten neuere Studien zeigen, dass die glatten Muskelzellen der 
pulmonalen Widerstandsgefäße Effektorzellen darstellen. Des Weiteren konnte 
nachgewiesen werden, dass Mediatoren - wie 5-Hydroxytryptamin (5-HT) und 
Endothelin-1 - die akute HPV modulieren und ein nicht selektiver Kationen-Kanal 
(TRPC6-Kanal) sowie die Aktivierung der Rho-Kinase wesentlich an der akuten HPV 
beteiligt sind. 
Bei chronischer Hypoxie, wie sie z. B. bei dauerhaftem Aufenthalt in großen Höhen 
entsteht, kommt es zu einer globalen Vasokonstriktion der Lunge. Die Folge ist ein 
pulmonaler Bluthochdruck mit einer Hypertrophie der glatten Muskulatur der 
Pulmonalgefäße („pulmonales vaskuläres Remodelling“). Hinzu kommt, dass eine 
dauerhafte Hypoxie zur Produktion von endothelialen Substanzen führt, die sowohl 
die Kontraktilität als auch die Proliferation der glatten Muskelzellen beeinflussen. Es 
konnte in mehreren Studien nachgewiesen werden, dass eine chronische Hypoxie zu 
einer verminderten Bildung von Stickstoffmonoxid und Prostazyklinen sowie zu einer 
vermehrten Produktion von 5-HT, Endothelin-1 und verschiedenen 
Wachstumsfaktoren führt. Über eine Beteiligung des 5-HT-Transporters, der TRPC-
Kanäle und der Rho-Kinase in der chronischen Hypoxie-bedingten pulmonalen 
Hypertension wird ebenfalls diskutiert. 
Enzyme der Cytochrom P450 (CYP)-Epoxygenase-Familie werden extrahepatisch 
vor allem im Herz, dem Gefäßsystem, dem Gastrointestinaltrakt, der Niere und der 
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Lunge exprimiert. Diese liefern durch Metabolisierung von Arachidonsäure vier 
verschiedene Isomere der Epoxyeicosatriensäuren (5,6-, 8,9-, 11,12-, und 14,15-
EETs), die sowohl den Gefäßtonus modulieren als auch antiinflammatorische und 
angiogenetische Eigenschaften haben. Nach ihrer Synthese stehen den EETs zwei 
Wege offen: Zum einen können sie in Phospholipide inkorporiert, zum anderen durch 
die Cyclooxygenase (5,6-EET) und die lösliche Epoxidhydrolase (sEH; 8,9-, 11,12- 
und 14,15-EET) zu ihren weniger aktiven Dihydroxyeicosatriensäuren (DHETs) 
metabolisiert werden. In Koronar- und Nierenarterien unterschiedlicher Spezies 
stellen EETs den sogenannten endothelialen hyperpolarisierenden Faktor dar, der 
zur Hyperpolarisation und Relaxation der glatten Gefäßmuskulatur führt. Kürzlich 
konnte unsere Arbeitsgruppe nachweisen, dass 11,12-EET die Agonisten-induzierte 
endotheliale Hyperpolarisation durch Translokation des TRRPC6-Kanals in mit 
Caveolin-1 angereicherte Membrangebiete, erhöht. Des Weiteren legen 
verschiedene Untersuchungen eine Verbindung zwischen der sEH und 
kardiovaskulären Erkrankungen nahe, da eine Hemmung dieses Enzyms der 
Entstehung einer Hypertonie entgegenwirkt.  
Dagegen ist die Rolle von CYP-Epoxygenase-generierten EETs und der sEH in der 
pulmonalen Zirkulation weitgehend unbekannt. Hierzu wurden in den letzten Jahren 
widersprüchliche Ergebnisse publiziert. Jedoch konnte unsere Arbeitsgruppe vor 
kurzem nachweisen, dass eine CYP-Epoxygenase in die HPV und das chronische 
Hypoxie-induzierte  pulmonale vaskuläre Remodelling involviert ist. Ziel der 
vorliegenden Arbeit war es daher, ausführlich die Rolle der sEH und der CYP-
Epoxygenase-generierten EETs in der akuten und chronischen HPV sowie im 
Hypoxie-bedingten pulmonalen vaskulären Remodelling zu analysieren. Dazu 
wurden CYP-Epoxygenase-Inhibitoren, ein EET-Antagonist und sEH-Inhibitoren 
verwendet. Um den molekularen Mechanismus der Hypoxie- und EET-induzierten 
pulmonalen Vasokonstriktion und des pulmonalen vaskulären Remodelling zu 
untersuchen, wurden kultivierte pulmonale glatte Muskelzellen, Promotor-Aktivitäts-
Assays und genetisch veränderte Tiere (sEH
-/- und TRPC6
-/- Mäusen) verwendet. 
Zunächst wurde die Rolle der sEH und EETs in der akuten HPV anhand der 
isolierten perfundierten Mauslunge untersucht. In Lungen von Wildtyp-Mäusen führte 
eine Hemmung der sEH zu einer deutlichen Steigerung der Amplitude der akuten 
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HPV. Darüber hinaus konnte nachgewiesen werden, dass eine vorherige Inkubation 
mit CYP-Epoxygenase-Inhibitoren oder dem EET-Antagonisten 14,15-EEZE den 
Effekt der sEH-Inhibitoren auf die akute HPV signifikant reduzierte. Im Vergleich zu 
Lungen von Wildtyp-Mäusen zeigten sEH
-/--Lungen eine deutlich erhöhte akute 
Hypoxie-bedingte Vasokonstriktion. Erwartungsgemäß hatte eine Hemmung der sEH 
in Lungen von sEH
-/--Mäusen keine Wirkung, während MSPPOH, ein CYP-
Epoxygenase-Inhibitor, und 14,15-EEZE die gesteigerte HPV signifikant reduzierten. 
Weiterhin konnte in der vorliegenden Arbeit bewiesen werden, dass eine hypoxische 
Inkubation (1% O2, 10 Minuten) von Maus-Lungenmikrosomen die EET-Produktion 
erheblich steigerte. Dieser Effekt war deutlich potenziert in Lungenmikrosomen von 
sEH
-/--Mäusen. Eine exogene Applikation von 11,12-EET in der isolierten 
perfundierten Mauslunge steigerte signifikant den basalen pulmonalarteriellen Druck 
und die akute HPV, während 14,15-EET und 11,12-DHET keine Effekte auf den 
pulmonalarteriellen Druck ausübten. Eine Inhibition des 5-HT2A-Rezeptors oder der 
Rho-Kinase führte sowohl zu einer deutlichen Reduktion der 11,12-EET-induzierten 
Vasokonstriktion, als auch zu einer signifikanten Hemmung der durch die EET und 
sEH-Inhibition gesteigerten akuten HPV. In isolierten Lungen von Wildtyp- und sEH
-/--
Mäusen führte eine hypoxische Präkonditionierung (hypoxische Ventilation der 
isolierten Lunge für 10 Minuten) zu einer Verstärkung der 5-HT-induzierten 
Vasokonstriktion. Der Verlust der sEH-Aktivität, entweder durch Einsatz spezifische 
Hemmstoffe oder durch genetische Deletion, führte zu einer weiteren deutlichen 
Verstärkung der 5-HT Dosiswirkungskurve nach hypoxischer Vorbehandlung. In 
pulmonalarteriellen glatten Muskelzellen, die TRPC6 überexprimieren, konnte 
nachgewiesen werden, dass 11,12-EET diesen Kanal durch Translokation in mit 
Caveolin-1 angereicherte Membrangebiete, aktiviert. Darüber hinaus führte eine 
akute Hypoxie in TRPC6-überexprimierenden glatten Muskelzellen ebenfalls zu einer 
TRPC6-Kanal-Translokation.  Dieser Effekt wurde durch den EET-Antagonisten 
deutlich gehemmt. Ferner konnte gezeigt werden, dass die EET-induzierte 
TRPC6-Translokation durch einen 5-HT2A-Rezeptor-Antagonisten reduziert wurde, 
wogegen ein Rho-Kinase-Inhibitor ohne Effekt war. Außerdem bewirkte eine akute 
Hypoxie und die Zugabe von 11,12-EET einen Anstieg des pulmonalarteriellen 
Drucks in isolierten perfundierten Lungen von TRPC6
+/--Mäusen. TRPC6
-/--Mäuse 
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reagierten auf keinen der beiden Stimuli. Diese Befunde zeigen, dass die Aktivität 
der sEH und CYP-Epoxygenase-generierte EETs die akute HPV modulieren und die 
EET-induzierte Kontraktion unter normoxischen und hypoxischen Bedingungen über 
einen TRPC6-Kanal-, einen 5-HT2A-Rezeptor-abhängigen Signaltransduktionsweg 
und die Aktivierung der Rho-Kinase verläuft. 
Ein weiteres Ziel der vorliegenden Arbeit war, die Rolle der sEH in der Entwicklung 
einer Hypoxie-bedingten pulmonalen Hypertension und des pulmonalen vaskulären 
Remodelling aufzuklären. Dafür wurden Mäuse 21 Tage in Hypoxie-Kammern 
hypoxischen Bedingungen (10% O2) ausgesetzt oder unter normoxischen 
Bedingungen gehalten. Eine chronische Hypoxie führte in Wildtyp-Mäusen zu einer 
verminderten pulmonalen Expression und folglich auch Aktivität der sEH. Zusätzlich 
induzierte eine dauerhafte Hypoxie eine Rechtsherzhypertrophie und Hämatopoese 
in Wildtyp-Mäusen und erhöhte signifikant die Anzahl der teil- und 
vollmuskularisierten pulmonalen Widerstandsgefäße. In isolierten perfundierten 
Lungen aus chronisch hypoxischen Mäusen war der Basisdruck signifikant erhöht 
und die akute HPV deutlich potenziert. Während der sEH-Inhibitor 1-Adamantyl-3-
Cyclohexylurea die akute HPV in Lungen von Tieren, die unter normoxischen 
Bedingungen gehalten wurden, steigerte, hatte er keinen Effekt auf die Antwort in 
Lungen von chronisch hypoxischen Mäusen. Der EET-Antagonist 14,15-EEZE 
hemmte signifikant den sEH-Inhibitor-induzierten Anstieg der akuten HPV in 
normoxischen Lungen und reduzierte die potenzierte akute HPV in Lungen von 
chronisch hypoxischen Tieren. sEH
-/--Mäuse zeigten im Vergleich zu Wildtyp-Mäusen 
eine verstärkte Hypoxie-induzierte Rechtsherzhypertrophie und Hämatopoese. 
Darüber hinaus konnte in Lungen von hypoxischen und normoxischen sEH
-/--Mäusen 
eine erhöhte Muskularisierung der pulmonalen Widerstandsgefäße nachgewiesen 
werden. Außerdem zeigten sEH
-/--Lungen eine verstärkte akute HPV. Eine vorherige 
hypoxische Exposition hatte keinen potenzierenden Effekt auf die akute HPV. 
Allerdings reduzierte 14,15-EEZE die akute HPV in sEH
-/--Lungen auf das Niveau der 
HPV von normoxischen Wildtyp-Lungen. Überdies führte Hypoxie (1% O2, 
24  Stunden) in humanen embryonalen Nierenzellen (HEK 293), die mit sEH 
Promotor-Konstrukten transfiziert wurden, zu einer verminderten sEH-Promotor-
Aktivität. Über die Expression der sEH in Lungen von Patienten mit pulmonaler 
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Hypertonie ist bisher wenig bekannt. In pulmonalen Gewebeschnitten des 
lungengesunden Kontrollkollektivs konnte eine starke sEH-Expression in der Media 
der Pulmonalarterien nachgewiesen werden, während in Gewebeschnitten von 
Patienten mit pulmonaler Hypertonie keine sEH-Expression detektiert werden 
konnte. Zusammenfassend legen die Resultate des zweiten Teils dieser Arbeit nahe, 
dass die sEH in die Entstehung der Hypoxie-bedingten pulmonalen Hypertension 
und des daraus folgenden pulmonalen vaskulären Remodellings involviert ist. 
Die Ergebnisse der vorliegenden Arbeit zeigen, dass die Aktivität/Expression der 
sEH die akute hypoxische Vasokonstriktion sowie die chronische HPV und die damit 
einhergehenden Veränderungen der pulmonalen Gefäße beeinflusst. Ihren Effekt 
vermittelt die sEH über den Abbau der vasokonstringierenden EETs - vor allem ist 
hier 11,12-EET relevant - zu weniger aktiven Diolen. Außerdem konnte hier 
nachgewiesen werden, dass an der EET-induzierten Vasokonstriktion unter 
normoxischen und unter akut hypoxischen Bedingungen der TRPC6-Kanal, der 
5-HT2A-Rezeptor und die Rho-Kinase an der Signaltransduktion beteiligt sind. Wie 
chronische Hypoxie die Aktivität/Expression der sEH und folglich auch die 
Entwicklung einer pulmonalen Hypertension und des pulmonalen vaskulären 
Remodelling beeinflusst, bleibt offen. Gleiches gilt für eine Involvierung des für die 
akute HPV beschriebenen Signaltransduktionsweges (5-HT2A-Rezeptor, TRPC6-
Kanal) in diese Prozesse. In verschiedenen Studien wurde nachgewiesen, dass 
TRPC6-Kanäle in pulmonaler Hypertension verstärkt exprimiert werden. TRPC6
-/--
Mäuse zeigten im Vergleich zu Wildtyp-Mäusen jedoch keine Unterschiede in der 
Entwicklung einer chronisch Hypoxie-induzierten pulmonalen Hypertension. sEH-
Inhibitoren werden momentan für den Einsatz in der Therapie der Hypertonie 
entwickelt. Angesichts der Tatsache, dass eine CYP-Epoxygenase, EETs und die 
Aktivität/Expression der sEH in die HPV und in das chronische Hypoxie-induzierte 
pulmonale vaskuläre Remodelling involviert sind, besteht die Möglichkeit, dass diese 
Substanzen die Entwicklung einer pulmonalen Hypertension fördern. 
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Abbreviations  
14,15-EEZE 14,15-epoxyeicosa-5(Z)-enoic acid  
5-HT 5-hydroxytryptamine 
5-HTT  5-HT transporter  
ACU 1-adamantyl-3-cyclohexylurea   
AEPU 1-adamantan-1-yl-3-{5-[2-(2-ethoxyethoxy)ethoxy]pentyl]}urea 
AMP adenosine  monophosphate   
ATP adenosine  triphosphate   
BMPR-II bone  morphogenetic  protein receptor type II 
Ca
2+ calcium 
cADP  cyclic adenosine diphosphate 
cAMP  cyclic adenosine monophosphate 
cPLA2 cytosolic phospholipase A2  
CYP  cytochrome P450  
DAG diacylglycerol 
DHET dihydroxyeicosatrienoic  acids 
DMSO dimethyl  sulfoxide 
DTT dithiothreitol 
EDHF endothelium-derived  hyperpolarizing factor 
EDTA ethylenediaminetetraacetic acid  
EET epoxyeicosatrienoic  acid 
Em  cellular membrane potential 
EpO epoxystearic  acid 
EpOME epoxyoctadecenoic  acids 
ERK  extracellular signal regulated kinase 
FAD  flavin adenine dinucleotide  
FMN flavin  mononucleotide 
G G  protein 
GFP  green fluorescent protein  
Grb  growth factor receptor-bound protein 
GRF  guanine nucleotide releasing factor;  
HETE hydroxyeicosatetraenoic  acid 
HIF hypoxia-inducible  factor 
HPV  hypoxic pulmonary vasoconstriction  
  100Abbreviations 
IgG immunoglobulin  G 
IP3 inositol-1,4,5-trisphosphate; 
IκB inhibitor  of  κB  
LC-MS/MS liquid  chromatography tandem mass spectrometry 
LTA4 leukotriene A4
LV + S  left ventricle and septum 
LVP  left ventricle pressure 
MAPK  mitogen-activated protein kinase 
mEH  microsomal epoxide hydrolase 
MLC  myosin light chain 
MLK  mixed lineage kinase 
MSPPOH  methyl sulphonyl propargyloxyphenyl hexanamide 
NADPH  nicotinamide adenine dinucleotide phosphate 
NFκB nuclear  factor  κB  
NO  nitric oxide  
NOX NADPH  oxidase 
O2
- superoxide anion  
P phosphate 
PAP  pulmonary artery pressure  
PASMC  pulmonary artery smooth muscle cell 
PBS phosphate  buffered  saline 
PCR  polymerase chain reaction 
PDGF  platelet derived growth factor 
PGI2 prostacyclin 
PI3K  phosphotidylinositol 3-kinase  
PKA  protein kinase A  
PKC  protein kinase C  
PLC phospholipase  C 
PMSF phenylmethanesulphonylfluoride 
pO2 oxygen partial pressure 
ROS  reactive oxygen species 
RTK  receptor tyrosine kinase 
RV right  ventricle 
SDS sodiumdodecylsulfatepolyacrylamide  
sEH  soluble epoxide hydrolase 
sGC  soluble guanylate cyclase 
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SR sarcoplasmic  reticulum 
STIM  stromal interacting molecule  
TBST  TRIS buffered saline with Tween  
TGF-β  transforming growth factor-β  
TNF-α  tumor necrosis factor-α  
TP tracheal  pressure 
TRIS trishydroxymethylaminomethane 
TRP  transient receptor potential 
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